Exhibit 10.4
EXECUTION VERSION

SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT
FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN
MARKED AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [***]
DATED
30 May 2018

            

DENALI THERAPEUTICS INC. (1)
THE SELLERS (2)
and
SHAREHOLDER REPRESENTATIVE SERVICES LLC (as the Sellers’ Representative) (3)

__________________________________________________________________________
SHARE PURCHASE AGREEMENT
relating to the entire issued share capital of
F-STAR GAMMA LIMITED
___________________________________________________________________________

cooleylogo.jpg [cooleylogo.jpg]

COOLEY (UK) LLP, DASHWOOD, 69 OLD BROAD STREET, LONDON EC2M 1QS, UK
T: +44 (0) 20 7583 4055 F: +44 (0) 20 7785 9355 WWW.COOLEY.COM
CONFIDENTIAL
 
 

--------------------------------------------------------------------------------

CONTENTS
1.
INTERPRETATION
 
5

2.
SALE AND PURCHASE
 
16

3.
CONSIDERATION
 
17

4.
POST COMPLETION ADJUSTMENTS
 
19

5.
COMPLETION
 
20

6.
ESCROW ACCOUNT
 
21

7.
SELLER WARRANTIES AND INDEMNITY
 
23

8.
LIMITATIONS TO THE SELLERS’ LIABILITY
 
24

9.
BUYER’S WARRANTIES
 
24

10.
POST COMPLETION MATTERS
 
25

11.
BUYER GUARANTEE
 
26

12.
SELLERS’ REPRESENTATIVE
 
28

13.
PAYMENTS
 
32

14.
ANNOUNCEMENTS
 
32

15.
CONFIDENTIALITY
 
33

16.
COSTS
 
34

17.
GENERAL
 
34

18.
ENTIRE AGREEMENT
 
35

19.
ASSIGNMENT
 
35

20.
NOTICES
 
36

21.
COUNTERPARTS
 
37

22.
GOVERNING LAW
 
37

23.
DISPUTE RESOLUTION
 
37

24.
PROCESS AGENTS
 
38

25.
CONFLICT WAIVER
 
39

CONFIDENTIAL
2

 

--------------------------------------------------------------------------------

Agreed Form Documents
1.
Disclosure Letter

2.
Escrow Agreement

3.
Loan Notes Instrument

4.
Press Release

CONFIDENTIAL
3

 

--------------------------------------------------------------------------------

THIS SHARE PURCHASE AGREEMENT is executed and delivered as a DEED on 30 May 2018

BETWEEN:

(1)    THE PERSONS, whose names and addresses are set out in Schedule 1 (the
“Sellers”);
(2)    DENALI THERAPEUTICS INC., a corporation organised and existing under the
laws of the State of Delaware, United States, having its principal place of
business at 201 Gateway Boulevard, South San Francisco, California, United
States (the “Buyer”); and
(3)    SHAREHOLDER REPRESENTATIVE SERVICES LLC, a Colorado limited liability
company and which is a party to this Agreement solely in its capacity as
representative of the Sellers (the “Sellers’ Representative”).
WHEREAS:
(A)
    The Company is a private limited liability company incorporated under the
laws of England and Wales and engaged in the delivery of therapeutics across the
blood brain barrier.

(B)
As at the date of this Agreement, the Sellers own the Shares that constitute the
entire issued share capital of the Company. The Sellers have agreed to sell to
the Buyer, and the Buyer has agreed to purchase and accept, the Shares on the
terms of this Agreement.

IT IS AGREED as follows:

CONFIDENTIAL
4

 

--------------------------------------------------------------------------------

1.
INTERPRETATION

1.1.
Definitions

In this Agreement:
“Accepted Fcab Target”
is defined in Schedule 5 (Contingent Consideration);
“Accounting Policies”
means the accounting policies and procedures set out in Part C of Schedule 4
(Accounting Policies);
“Accounts”
means the Company’s individual accounts (as that term is used in sections 394
and 395 of the Companies Act) and cash flow statement for the financial year
ended on the Last Accounting Date, the auditors’ report on those accounts, the
directors’ report for that year and the notes to those accounts;
“Actual Net Cash”
has the meaning given to it in Schedule 4.
“ADR”
has the meaning given to it in clause 23.2;
“Affiliate”
means, with respect to a party, any Person that, directly or indirectly, through
one (1) or more intermediaries, controls, is controlled by or is under common
control with such Party. For purposes of this definition, “control” and, with
correlative meanings, the terms “controlling”, “controlled by” and “under common
control with” means (a) the possession, directly or indirectly, of the power to
direct the management or policies of a Person, whether through the ownership of
voting securities, by contract relating to voting rights or corporate
governance, or otherwise; or (b) the ownership, directly or indirectly, of more
than fifty percent (50%) of the voting securities or other ownership interest of
a Person (or, with respect to a limited partnership or other similar entity, its
general partner or controlling entity). The parties acknowledge that in the case
of certain entities organized under the laws of certain countries outside of the
United States, the maximum percentage ownership permitted by law for a foreign
investor may be less than fifty percent (50%), and that in such case such lower
percentage shall be substituted in the preceding sentence, provided that such
foreign investor has the power to direct the management or policies of such
entity. “Affiliates” shall be construed accordingly;
“Business Day”
means a day (other than a Saturday or Sunday) on which banks generally are open
for business in London, UK;
“Business Warranty”
means [***];
“Business Warranty Claim”
means a claim by the Buyer for breach of a Business Warranty;

CONFIDENTIAL
5
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

“Buyer’s Account”
means the bank account notified by the Buyer to the Sellers’ Representative from
time to time;
“Buyer’s Group”
means the Buyer and the Buyer’s Group Undertakings;
“Buyer’s Group Undertaking”
means the Buyer or an undertaking which is a subsidiary undertaking or parent
undertaking of the Buyer or a subsidiary undertaking of a parent undertaking of
the Buyer and, for the avoidance of doubt, includes the Company from Completion,
and “Buyer’s Group Undertakings” shall be construed accordingly;
“Cash”
means the aggregate of all cash held by the Company immediately following
Completion, but excluding the Pass Through Amount;
“Cash Sellers”
means each of the Sellers other than the Loan Note Sellers;
“Claim”
means any Business Warranty Claim, Tax Warranty Claim, Special Indemnity Claim
(including any Fraud Claim), Warrantor Fundamental Warranty Claim and/or
Fundamental Warranty Claim, and “Claims” means any two or more of them;
“Company”
means F-star Gamma Limited, a private limited company incorporated under the
laws of England and Wales under company number 10214672, having its registered
office at Eddeva B920, Babraham Research Campus, Cambridge CB22 3AT;
“Company Confidential Information”
means any Information or data relating to any Fcab or mAb2 Product, any
Exploitation of any Fcab or mAb2 Product, any Know-How with respect thereto
developed by or on behalf of Company or its Affiliates, or the scientific,
regulatory or business affairs or other activities of the Company;
“Completion”
means completion of the sale and transfer of the Shares to the Buyer in
accordance with the terms of this Agreement;
“Completion Accounts”
means the Draft Completion Accounts which have been agreed or determined in
accordance with Part A of Schedule 4 (Preparation of Completion Accounts);
“Completion Date”
means the date on which Completion occurs;
“Contingent Consideration”
has the meaning given to it in paragraph 1 of Part A of Schedule 5 (Contingent
Consideration);
“Contingent Consideration Loan Notes”
means the loan notes which may become issuable by the Buyer to certain of the
Sellers following Completion pursuant to clause 3.5 and/or paragraph 2.3 of
Schedule 5 (Contingent Consideration), to be constituted by the Loan Notes
Instrument;
“control”
has the meaning given to it in section 1124 of the Corporation Tax Act 2010 and
“controlling” shall be construed accordingly;

CONFIDENTIAL
6
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

“Declared Distributions”
means all dividends and other distributions resolved or declared to be paid or
made, by the Company in respect of the Shares by reference to a record date
which falls on or before Completion;
“Defaulting Party”
has the meaning given to it in clause 5.4;
[***]
has the meaning given to it in the definition of “Initial Amount”;
“Denali Fcab Notice”
has the meaning given to it in the License Agreement;
[***]
has the meaning given to it in the definition of “Initial Amount”;
“Determination Date”
means the date on which the Completion Accounts are agreed or determined in
accordance with the provisions of Part A of Schedule 4 (Preparation of
Completion Accounts);
“Develop” or “Development”
has the meaning given to it in the License Agreement;
“Disclosure Documents”
means the documents attached to the Disclosure Letter;
“Disclosure Letter”
means the letter from the Warrantors to the Buyer in relation to the Warranties
and including the Disclosure Documents having the same date as this Agreement,
the receipt of which has been acknowledged by the Buyer;
“Dispute”
has the meaning given to it in clause 23.1;
“Disputed Business Warranty Claim”
means any Business Warranty Claim that is not yet a Settled Business Warranty
Claim, and “Disputed Business Warranty Claims” shall be construed accordingly;
“Draft Completion Accounts”
means a statement of assets and liabilities for the Company as at the Effective
Time, in the form and with the line items set out in Part B of Schedule 4
(Completion Accounts) and which has been prepared in accordance with Part A of
Schedule 4 (Preparation of Completion Accounts);
“Effective Time”
means 5 p.m. (London time) on the Completion Date;
“Encumbrance”
means a mortgage, charge, pledge, lien, option, restriction, right of first
refusal, right of pre-emption, third-party right or interest, other encumbrance
or security interest of any kind, or another type of preferential arrangement
(including a title transfer or retention arrangement) having similar effect,
including any such right or interest arising at Completion or otherwise in
connection with this Agreement, and “Encumbrances” shall be construed
accordingly;
“Escrow Account”
means the separately designated interest bearing US dollar deposit account with
SunTrust Bank opened by the Escrow Agent and operated in accordance with the
Escrow Agreement into which payment of the Escrow Amount will be made by the
Buyer at Completion;

CONFIDENTIAL
7
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

“Escrow Agent”
means SunTrust Bank to be appointed pursuant to the Escrow Agreement;
“Escrow Agreement”
means the agreement in the agreed form between the Buyer, the Sellers’
Representative and the Escrow Agent in relation to the Escrow Account;
“Escrow Amount”
means [***];
“Estimated Net Cash”
means such amount in US dollars as is notified in writing by the Sellers to the
Buyer no later than 10 Business Days prior to the Completion Date that is the
good faith estimate by the Sellers of the Net Cash as at the Effective Time;
“Exercise Notice”
has the meaning given to it in the Option Agreement;
“Exploitation”
has the meaning given to it in the License Agreement;
“F-star”
means F-star Biotechnology Limited, a private limited company incorporated under
the laws of England and Wales under company number 08067987, having its
registered office at Eddeva B920, Babraham Research Campus, Cambridge CB22 3AT;
“F-star GmbH”
means F-star Biotechnologische Forschungs-und entwicklungsges.m.b.h, a limited
liability company incorporated under the laws of the Republic of Austria;
“Fairly Disclosed”
has the meaning given to it in clause 7.5;
“Fcab Delivery”
is defined in Schedule 5 (Contingent Consideration);
“Fraud Claim”
means a claim in respect of fraud, wilful misconduct or wilful concealment by
any of Warrantors (individually or on behalf of the Company) prior to
Completion;
“Fundamental Warranty”
Means [***] and “Fundamental Warranties” means [***];
“Fundamental Warranty Claim”
means a claim by the Buyer for breach of a Fundamental Warranty;
“Gamma IP License”
means that certain license agreement between the Company and F-star dated 24
August 2016;
“Gamma Service Agreement”
means that certain services agreement between the Company and F-star dated 24
August 2016;
“Guaranteed Obligations”
means all present and future payment obligations and liabilities of the Company
due, owing or incurred under clause 7.5.2 of the Gamma IP License to F-star
(including, without limitation, under any amendment, supplement or restatement
of the Gamma IP License; provided such amendment, supplement or restatement
shall not increase the obligations of the Buyer without the express consent of
the Buyer);
“HMRC”
means HM Revenue & Customs;

CONFIDENTIAL
8
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

“Indebtedness”
means the aggregate amount (expressed as a positive number) immediately
following Completion of the following:
a)    the principal and accrued interest on any outstanding borrowing or
indebtedness in the nature of borrowing incurred by the Company including,
without limitation, bank debt, loans, overdrafts, guarantees of indebtedness,
letters of credit (which are secured by a third party), any loan notes or bonds,
any other interest bearing and/or secured lending or credit liabilities provided
by third parties to the Company and any early repayment, prepayment, or break
costs, fees or penalties in respect of any such items and any legal costs and
expenses in connection with the release of security in relation to any such
borrowings;
b)    all deferred indebtedness of the Company for the payment of the purchase
price of property or assets purchased or services rendered (other than up to
[***] of trade payables and other current liabilities incurred in the ordinary
course of business);
c)    all obligations of the Company to pay rent or other payment amounts under
any lease up to and including the Completion Date;
d)    reimbursement obligations of the Company with respect to letters of
credit, bankers’ acceptances or similar facilities issued for the account of the
Company and that are outstanding as at the Completion Date;
e)    all obligations under any interest rate swap agreement, forward rate
agreement, interest rate cap or collar agreement or other financial agreement or
arrangement to which the Company is a party and which was entered into for the
purpose of limiting or managing interest rate risks,
f)    all obligations secured by any Encumbrance existing on property owned by
the Company;

CONFIDENTIAL
9
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

 
g)    all premiums, penalties, fees, expenses, breakage costs and change of
control payments required to be paid or offered in respect of any of the
foregoing clauses (b) through (e) as a result of the consummation of the
transactions contemplated by this Agreement or in connection with any lender
consent;
h)    all guaranties, endorsements, assumptions and other contingent obligations
of the Company in respect of, or to purchase or to otherwise acquire, any of the
obligations and other matters of the kind described in any of the clauses (a)
through (g) appertaining to third parties; and
i)    all liabilities for Taxes incurred by the Company up to, but not paid by,
Completion;
“Information”
means all knowledge of a technical, scientific, business and other nature,
including know-how, technology, means, methods, processes, practices, formulae,
instructions, skills, techniques, procedures, experiences, ideas, technical
assistance, designs, drawings, assembly procedures, computer programs,
apparatuses, specifications, data, results and other material, regulatory data,
and other biological, chemical, pharmacological, toxicological, pharmaceutical,
physical and analytical, pre-clinical, clinical, safety, manufacturing and
quality control data and information, including study designs and protocols,
reagents (e.g., plasmids, proteins, cell lines, assays and compounds) and
biological methodology; in each case (whether or not confidential, proprietary,
patented or patentable, of commercial advantage or not) in written, electronic
or any other form now known or hereafter developed;
“Initial Amount”
means, where the Buyer serves an Exercise Notice on the Sellers’ Representative
and the Company in accordance with the Option Agreement:
a)    on a date prior to both [***];
b)    on a date that is [***];
c)    on a date that is [***]; or
d)    after the time period in paragraph (c) above of this definition, [***];

CONFIDENTIAL
10
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

“Intellectual Property
means all intellectual property rights, whether registered or not, including
pending applications for registration of such rights and the right to apply for
registration or extension of such rights including patents, petty patents,
utility models, design patents, designs, copyright (including moral rights and
neighbouring rights), database rights, rights in integrated circuits and other
sui generis rights, trade marks, trading names, company names, service marks,
logos, the get-up of products and packaging and other signs used in trade,
internet domain names, Know How and any rights of the same or similar effect or
nature as any of the foregoing anywhere in the world;
“Know How”
means any and all data, inventions, methods, proprietary information, processes,
trade secrets, techniques and technology, whether patentable or not but which
are not generally known, including discoveries, formulae, materials (including
chemicals), biological materials (including expression constructs, nucleic acid
sequences, amino acid sequences, and cell lines), practices, test data
(including pharmacological, toxicological, pre-clinical and clinical information
and test data), analytical and quality control data (including drug stability
data), manufacturing technology and data (including formulation data), and sales
forecasts, data and descriptions;
“Last Accounting Date”
means 31 December of the financial year on which the Company’s last audited
financial statements and accounts were last required to be filed with the UK
Registrar of Companies;
“License Agreement”
means that certain license and collaboration agreement among the Buyer, the
Company, F-star GmbH and F-star, dated 24 August 2016;
“Loan Note Escrow Account”
means the separately designated interest bearing US dollar deposit account with
SunTrust Bank opened by the Escrow Agent and operated in accordance with the
Escrow Agreement into which payment of such amounts as required by clause 3.6
will be made by the Buyer;
“Loan Note Sellers”
each of the Sellers in Schedule 1 marked with an asterisk (*);
“Loan Notes Instrument”
means the loan notes instrument to be issued by the Buyer in the agreed form;
“Management Accounts”
means the unaudited monthly management accounts of the Company in respect of the
period starting on the day after the Last Accounting Date and ending on the last
day of the calendar month preceding the date of this Agreement for which such
accounts have been prepared;
“Material Contract”
has the meaning given to it in clause 7.1.1 of Schedule 7;

CONFIDENTIAL
11
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

“Maximum Contingent Consideration”
means:
a)    in the event of a [***], provided that if an Initial Payment True Up Event
subsequently occurs, then the Maximum Contingent Consideration will be [***];
b)    in the event of a [***], provided that if an Initial Payment True Up Event
subsequently occurs, then the Maximum Contingent Consideration will be [***];
c)    in the event of a [***]; or
d)    in the event of a [***];
“Net Cash”
means an amount (which may be a positive or a negative number) equal to the Cash
less the Indebtedness, less Transaction Costs and less Declared Distributions;
“Non-defaulting Party”
has the meaning given to it in clause 5.4;
“Notice”
has the meaning given to it in clause 20.1;
“Option Agreement”
means that certain option agreement related to the entire issued share capital
of the Company among Buyer, the Company, the Sellers, and the Sellers’
Representative, dated 24 August 2016;
“Pass Through Amount”
means amounts payable by the Company to F-star pursuant to (i) clause 7.5.2 of
the Gamma IP License that have been received by the Company from the Buyer
pursuant to the License Agreement but not paid to F-star as of the Completion
Date;
“Payments Administrator”
means Acquiom Clearinghouse LLC, a Delaware limited liability company;
“Payment Date”
has the meaning given to it in paragraph 1 of Part A of Schedule 5 (Contingent
Consideration);
“Person”
means an individual, sole proprietorship, partnership, limited partnership,
limited liability partnership, corporation, limited liability company, business
trust, joint stock company, trust, unincorporated association, joint venture or
other similar entity or organization, including a government or political
subdivision, department or agency of a government;
[***]
has the meaning given to it in the definition of “Initial Amount”;
[***]
has the meaning given to it in the definition of “Initial Amount”;
“Preliminary Determination Proceeding”
has the meaning given to it in paragraph 11.2 of Schedule 8 (Limitations on
Sellers’ Liability);
“Press Release”
means a press release regarding Completion in a form agreed between the Buyer
and the Sellers;
“Proportion of Initial Consideration”
has the meaning given to it in clause 3.9;

“Release Date”
means the date which is [***] from Completion;

CONFIDENTIAL
12
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

“Relevant Shares”
means, in relation to each Seller, the number and class of Shares held as at
Completion set out adjacent to that Seller’s name in columns B and C of Schedule
1 (The Sellers);
“Relief”
means any loss, relief, exemption, allowance, deduction, credit or set-off in
respect of Tax or relevant to the computation of Tax and any right to repayment
of Tax;
“Sellers’ Majority”
means such of the Sellers who, immediately prior to Completion, together held
not less than a majority in number of the Shares (as determined by reference to
the Shares set out adjacent to each relevant Seller’s name in column B of
Schedule 1 (The Sellers));
“Set Off Claim”
has the meaning given to it in paragraph 11.2 of Schedule 8 (Limitations on
Sellers’ Liability);
“Set Off Dispute Notice”
has the meaning given to it in paragraph 11.2 of Schedule 8 (Limitations on
Sellers’ Liability);
“Set Off Notice”
has the meaning given to it in paragraph 11.2 of Schedule 8 (Limitations on
Sellers’ Liability);
“Settled Business Warranty Claim”
means a Business Warranty Claim or part of a Business Warranty Claim the quantum
of which is:
a)    agreed in writing between the Buyer and the Sellers’ Representative;
b)    determined by [***] court of competent jurisdiction; or
c)    determined pursuant to the procedures set forth in clause 23.3;
“Settled Claim”
means a Settled Business Warranty Claim, or a Special Indemnity Claim,
Fundamental Warranty Claim, or Warrantor Fundamental Warranty Claim (or part
thereof), the quantum of which is:
a)    agreed in writing between the Buyer and the Sellers’ Representative;
b)    determined by [***] court of competent jurisdiction; or
c)    determined pursuant to the procedures set forth in clause 23.3;
“Shareholders’ Agreement”
means the shareholders’ agreement between the Shareholders and the Company dated
24 August 2016;
“Shareholder Arrangements”
means any advisory, contractual or commercial arrangements relating to the
Company (including the existing shareholders agreement relating to the Company)
to which any or all of the Sellers and/or any of their Affiliates are a party
(excluding any employment agreement or consultancy agreement between those
Sellers who are employees or consultants and the Company);
“Shares”
means all of the issued ordinary shares in the capital of the Company from time
to time;

CONFIDENTIAL
13
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

“Shortfall”
has the meaning given to it in clause 5.1(a);
[***]
has the meaning given to it in clause 6.3;
“Special Indemnity Claim”
means a claim in respect of any of the Special Indemnity Matters and
“Special Indemnity Claims” shall be construed accordingly;
“Special Indemnity Matter”
means [***] and “Special Indemnity Matters” means [***];
“Tax”, “Taxes” or “Taxation”
means all forms of taxation, duties and withholdings in respect of taxation
imposed in the United Kingdom or elsewhere (including National Insurance
contributions) and all interest, penalties, charges and fines in respect of any
of them;
“Tax Authority”
means HMRC and any other authority, body or official (whether in the United
Kingdom or elsewhere) competent to assess, demand, impose, administer or collect
Tax or make any decision or ruling on any matter relating to Tax;
“Tax Warranty”
means [***] and “Tax Warranties” means [***];
“Tax Warranty Claim”
means a claim in respect of any breach of any of the Tax Warranties;
“Third Party”
has the meaning given to it in the License Agreement;
“Total Consideration”
has the meaning given to it in clause 3.1;
“Total Contingent Consideration”
has the meaning given to it in paragraph 1 of Part A of Schedule 5 (Contingent
Consideration);
“Transaction Costs”
means all third party fees, costs, expenses, payments, and expenditures incurred
by the Company in connection with the transactions contemplated by this
Agreement whether or not billed or accrued (including any fees, costs expenses,
payments, and expenditures of legal counsel and accountants, the maximum amount
of fees costs, expenses, payments, and expenditures payable to financial
advisors, investment bankers and brokers of the Company notwithstanding any
contingencies for earnouts, escrows, etc., and any such fees, costs, expenses,
payments, and expenditures incurred by the Sellers paid for or to be paid for by
the Company);
“Transaction Documents”
means this Agreement, the Option Agreement, the License Agreement, the Gamma IP
License, the Loan Note Instrument, the Disclosure Letter, the Escrow Agreement
and the Gamma Service Agreement;
“Upfront Consideration”
has the meaning given to it in clause 3.2;

“Warrantor Fundamental Warranties”
means [***];

“Warrantor Fundamental Warranty Claim”
means a claim by the Buyer for breach of a Warrantor Fundamental Warranty;

CONFIDENTIAL
14
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

“Warrantors”
means [***], save that if any such person ceases to be employed or otherwise
engaged by F-star GmbH (or any of its Affiliates) in a management position or
ceases to own (legally or beneficially) Shares then they shall cease to be a
Warrantor and shall be replaced as a Warrantor by the person then performing the
role of [***], or, in any case, by such person as the Company, acting
reasonably, may nominate in writing provided that such person owns Shares
(legally or beneficially), performs a senior management role in the Company and
the Buyer consents to the appointment, such consent not to be unreasonably
withheld, conditioned or delayed, and a “Warrantor” means any one of them; and
“Warranty”
means [***] and “Warranties” means [***].

1.2.
Clause, Schedule and paragraph headings shall not affect the interpretation of
this Agreement.

1.3.
References to clauses and Schedules are to the clauses and Schedules of this
Agreement and references to paragraphs are to paragraphs of the relevant
Schedule.

1.4.
The Schedules form part of this agreement and shall have effect as if set out in
full in the body of this Agreement. Any reference to this agreement includes the
Schedules.

1.5.
A “subsidiary” or “holding company” is to be construed in accordance with
section 1159 (and Schedule 6) of the Companies Act and a “subsidiary
undertaking” or “parent undertaking” is to be construed in accordance with
section 1162 (and Schedule 7) of the Companies Act;

1.6.
A person includes a natural person, corporate or unincorporated body (whether or
not having separate legal personality).

1.7.
A reference to a party shall include that party’s personal representatives,
successors and permitted assigns.

1.8.
Unless the context otherwise requires, words in the singular shall include the
plural and in the plural shall include the singular.

1.9.
Unless the context otherwise requires, a reference to one gender shall include a
reference to the other genders.

1.10.
A reference to writing or written includes fax and e-mail (unless otherwise
expressly provided in this Agreement).

CONFIDENTIAL
15
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

1.11.
The ejusdem generis principle of construction shall not apply to this Agreement.
Accordingly, any words following the terms including, include, in particular,
for example or any similar expression shall be construed as illustrative and
shall not limit the sense of the words, description, definition, phrase or term
preceding those terms. Where the context permits, other and otherwise are
illustrative and shall not limit the sense of the words preceding them.

1.12.
A reference to a document in this Agreement in the agreed form is to a document
agreed by the parties and initialled by them or on their behalf for
identification purposes.

1.13.
Where any obligation in this Agreement is expressed to be undertaken or assumed
by any party, that obligation is to be construed as requiring the party
concerned to exercise all rights and powers of control over the affairs of any
other person which it is able to exercise (whether directly or indirectly) in
order to secure performance of the obligation.

1.14.
References to any English legal term for any action, remedy, method of judicial
proceeding, legal document, legal status, court, official or any other legal
concept shall, in respect of any jurisdiction other than England, be deemed to
include the legal concept which most nearly approximates in that jurisdiction to
the English legal term.

1.15.
A reference to a statute or statutory provision is a reference to it as amended,
extended or re-enacted from time to time.

1.16.
References to “US$” or “$” are references to US dollars, legal tender in the
United States, and references to “GBP” or “£” are references to pounds sterling,
legal tender in the United Kingdom.

2.
SALE AND PURCHASE

2.1.
Each Seller severally agrees to sell or procure the sale to the Buyer, and the
Buyer agrees to buy, all of such Seller’s Relevant Shares together with all
rights attaching to those Relevant Shares at Completion, free from any
Encumbrance and with full title guarantee.

2.2.
Each Seller severally waives all rights of pre-emption, rights of first refusal
and any other similar rights or other restrictions on transfer conferred on that
Seller by the Company’s articles of association or otherwise over any of the
Relevant Shares.

2.3.
The Buyer shall be responsible for the payment of all stamp duty (and, if
applicable, stamp duty reserve tax) on this Agreement and the transfers in
respect of the Shares at Completion.

2.4.
In the event that the Buyer becomes aware that it or the Escrow Agent will have
an obligation to deduct or withhold an amount for or on account of Taxes from
any payment made under this Agreement, it shall notify the Sellers’
Representative in writing as soon as reasonably

CONFIDENTIAL
16
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

practicable and the parties shall use their reasonable endeavours to do, to the
extent within their power and authority, all such acts and things and to sign
all such documents as will enable them to take advantage of any applicable
double taxation agreement, treaty or domestic exemption which may apply to
eliminate or reduce withholding Taxes and otherwise provide the Sellers such
assistance as is reasonably required to obtain a refund of the withheld or
similar Taxes, or obtain a credit with respect to such Taxes. In the event there
is no applicable double taxation agreement, treaty or domestic exemption or if
an applicable double taxation agreement, treaty or domestic exemption reduces
but does not eliminate such withholding or similar Tax, the Buyer or Escrow
Agent shall deduct the amount paid from the amount due to the respective Seller
or Sellers, remit such withholding or similar Tax to the appropriate Tax
Authority and secure and send to the respective Seller or Sellers reasonable
evidence of the payment of such withholding or similar Tax. In the event that
any Taxes are required by applicable Tax law to be withheld or deducted for or
on account of Tax from any payments made under this Agreement, any Taxes so
withheld and deducted from any payment by the Buyer or the Escrow Agent and paid
over to the appropriate Tax Authority shall be treated as paid to the Sellers
under this Agreement.

3.
CONSIDERATION

3.1.
The purchase price for the Shares shall be an amount equal to:

(a)
the Upfront Consideration; and

(b)
any Contingent Consideration,

(collectively, the “Total Consideration”).
Upfront Consideration
3.2.
The aggregate consideration payable by the Buyer to the Sellers for the Shares
pursuant to this Agreement on the Completion Date shall be:

(a)
the Initial Amount; plus

(b)
the Estimated Net Cash,

(the amount set out in clause 3.2(a) plus the amount set out in clause 3.2(b)
being the “Initial Consideration”), as increased by the amount to be paid by the
Buyer or, as the case may be, decreased by the amount to be paid by the Sellers,
pursuant to clause 4.1 (the total sum being referred to as the “Upfront
Consideration).
3.3.
At Completion, the Buyer shall pay:

CONFIDENTIAL
17
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

(a)
an amount in cash equal to the Initial Consideration less the Escrow Amount, by
transfer of funds for same day value to the Payments Administrator in accordance
with clause 13.1; and

(b)
the Escrow Amount into the Escrow Account by transfer of funds for same day
value.

3.4.
The parties agree to comply with their respective obligations under Part A of
Schedule 4 (Preparation of Completion Accounts).

Contingent Consideration
3.5.
If any of the Milestone Events set forth in Schedule 5 (Contingent
Consideration) are achieved, the Buyer will make the corresponding Milestone
Payment to the Payments Administrator for further distribution to the Sellers on
or prior to the Payment Date. Any Contingent Consideration payable to the
Sellers shall be allocated between the Sellers with regard to their respective
Proportion of Initial Consideration or as otherwise notified to the Buyer in
writing by the Sellers’ Representative at least five (5) Business Days prior to
a Payment Date and shall be satisfied:

(a)
in respect of the Loan Note Sellers, by the issue by the Buyer of the Contingent
Consideration Loan Notes to each of the Loan Note Sellers equal, in principal
amount, to the relevant Contingent Consideration due to such Loan Note Sellers;
and

(b)
in respect of the Cash Sellers, by paying the relevant Contingent Consideration
due to each of the Cash Sellers to the Payments Administrator in accordance with
clause 13 on a Payment Date.

3.6.
Simultaneously with the issue by the Buyer of any Contingent Consideration Loan
Notes to the Loan Note Sellers in accordance with clause 3.5(a), the Buyer shall
transfer to the Loan Note Escrow Account an amount equal to the total aggregate
principal amount of such Contingent Consideration Loan Notes, which amount
(together with any interest accrued thereon) shall be released by the Escrow
Agent to the Loan Note Sellers within five (5) Business Days following
redemption of such Contingent Consideration Loan Notes in accordance with the
Loan Note Instrument. The Escrow Agent may withdraw from the Loan Note Escrow
Account an amount equal to any Tax on the interest earned in respect of money
held in the Loan Note Escrow Account for which it is liable.

3.7.
The Total Contingent Consideration shall not under any circumstances exceed the
Maximum Contingent Consideration.

3.8.
The Buyer shall (and shall procure that all relevant Buyer’s Group Undertakings
shall) comply with the provisions of Schedule 5 (Contingent Consideration).

CONFIDENTIAL
18
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

3.9.
The proportion of the Initial Consideration, to which each Seller is entitled is
set against his name in column D of Schedule 1 (The Sellers) (each, a
“Proportion of Initial Consideration”).

Consideration Generally
3.10.
Each Seller agrees to the allocation of the Total Consideration as provided for
in this Agreement (including any allocation notified to the Buyer by the
Sellers’ Representative pursuant to clause 3.5) and waives any claim or dispute
regarding the apportionment of the proceeds from the sale of his Shares provided
it is made in accordance with this Agreement. Following any payment to the
Payments Administrator in accordance with this Agreement, the Buyer shall be
under no obligation to see that any such amounts are divided and paid to each
Seller (or any other person).

3.11.
If, after Completion, any Seller is in or comes into possession of any amounts
attributable to any other Seller then as soon as reasonably practicable
following any request by the Seller which has the right to such amounts, the
relevant Seller shall use all reasonable endeavours to ensure that the person in
possession of that relevant amount does or causes to be done all such things as
the Seller entitled to such amount may from time to time reasonably require, in
order to transfer possession of such relevant amount to the owner.

4.
POST COMPLETION ADJUSTMENTS

4.1.
If the amount of the Actual Net Cash:

(a)
is less than the amount of the Estimated Net Cash, then, subject to clause 5.3,
the Sellers shall pay the Buyer an amount equal to the amount of such shortfall
(the “Shortfall”); or

(b)
exceeds the amount of the Estimated Net Cash, the Buyer shall pay the Sellers an
amount equal to the amount of such excess,

in either case, together with an amount equal to interest on such sum calculated
on a daily basis at a rate of [***] from (and including) the Completion Date to
(but excluding) the date of actual payment, in accordance with the provisions of
clauses 4.2 and 4.3.
4.2.
Payments made by the Buyer pursuant to clause 4.1(b) shall be made by transfer
of funds for same day value (to the Payments Administrator in accordance with
clause 13.1), within two (2) Business Days of the Determination Date without set
off, deduction or withholding (except as required by law or by this Agreement).

4.3.
If an amount is payable by the Sellers pursuant to clause 4.1(a), such amount
shall be paid from the Escrow Account to the Buyer when the Buyer and the
Sellers’ Representative within

CONFIDENTIAL
19
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

two (2) Business Days of the Determination Date jointly instruct the Escrow
Agent in writing to make such payment out of amounts standing to the credit of
the Escrow Account to the Buyer’s Account in accordance with clause 13.2.

5.
COMPLETION

5.1.
Completion shall take place at the offices of the Seller’s Solicitors
immediately following the execution of this Agreement.

5.2.
At Completion each Seller and the Buyer shall do all those things respectively
required of each of them in Schedule 3 (Completion Requirements).

5.3.
Neither the Sellers nor the Buyer are obliged to complete this Agreement unless:

(a)
all of the Sellers (in the case of the Buyer) or the Buyer (in the case of the
Sellers) comply with all its/their obligations under this clause 5 and Schedule
3 (Completion Requirements); and

(b)
subject to the provisions of clause 7 of the Option Agreement, the purchase of
all the Shares under this Agreement is completed simultaneously.

5.4.
If Completion does not take place immediately following the execution of this
Agreement because the Buyer or any Seller (the “Defaulting Party”) fails to
comply with any of its obligations under this clause 5 and Schedule 3
(Completion Requirements) (whether such failure amounts to a repudiatory breach
or not) (a “Material Default”), the Buyer (if the Defaulting Party is a Seller)
or the Company (if the Defaulting Party is the Buyer) (the “Non-defaulting
Party”) may by notice to the Defaulting Party:

(a)
proceed to Completion to the extent reasonably practicable (without limiting its
rights under this Agreement);

(b)
postpone Completion to such date as the Non-defaulting Party may specify; or

(c)
terminate this Agreement by notice in writing to the Defaulting Party (a
“Termination Notice”) save that the Non-defaulting Party shall have five (5)
Business Days from receipt of the Termination Notice to remedy such Material
Default (provided, however, that no such cure period shall be available or
applicable to any such Material Default which by its nature cannot be cured). In
the event that the Material Default is capable of being remedied but is not so
remedied within the requisite time period, this Agreement shall terminate upon
expiry of the period of five (5) Business Days without further action by either
party. If the Material Default is remedied within the requisite time, the
Termination Notice shall lapse and

CONFIDENTIAL
20
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

Completion shall be deemed to have been postponed until such date as the
Non-defaulting Party may determine.
5.5.
If the Non-defaulting Party postpones Completion to another date in accordance
with clause 5.4(b), or if Completion is deemed to have been postponed to another
date in accordance with clause 5.4(c), the provisions of this Agreement apply as
if that other date is the Completion Date.

5.6.
If the Non-defaulting Party terminates this Agreement pursuant to clause 5.4(c),
each party’s further rights and obligations cease immediately on termination,
but termination does not affect a party’s accrued rights and obligations at the
date of termination.

5.7.
The parties agree that except in the case of fraud, wilful misconduct or wilful
concealment on behalf of the Sellers or the Buyer, rescission shall not be
available as a remedy for any breach of this Agreement.

5.8.
Nothing in this clause 5 shall prevent a Non-defaulting Party from exercising
remedies available to it under applicable law.

6.
ESCROW ACCOUNT

6.1.
Each party agrees that the money in the Escrow Account shall only be used in
accordance with the provisions set out in clause 4, this clause 6, paragraph 5
of Part A of Schedule 4 (Preparation of Completion Accounts) and the Escrow
Agreement.

6.2.
Each party shall ensure that all rights to the Escrow Account remain free from
any Encumbrance, set off or counterclaim except as referred to in this clause 6.

6.3.
The liability of any Warrantor in respect of [***] shall be limited by the
amount of money standing to the credit of the Escrow Account from time to time
and the sole remedy of the Buyer under this Agreement in respect of a [***]
shall be the release of any such amount to the Buyer from the Escrow Account.

6.4.
A [***] must be satisfied out of and deducted from the money in the Escrow
Account in accordance with this clause 6 and a Shortfall must be first satisfied
out of and deducted from the money in the Escrow Account in accordance with this
clause 6. In addition, in the event of [***].

6.5.
To the extent that liability for [***] is to be satisfied from the Escrow
Account, each Warrantor shall be [***] liable to the Buyer for such liability up
to the availability of any amount standing to the credit of the Escrow Account
from time to time irrespective of the amount (if any) contributed to the Escrow
Account by such Warrantor.

CONFIDENTIAL
21
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

6.6.
No Warrantor shall have any liability to any other Seller in respect of any
liability satisfied from the Escrow Account.

6.7.
Clauses 6.3 and 6.6 shall not apply so as to limit the liability of any
Warrantor in respect of any fraud by such Warrantor or any remedy available to
any other Seller or the Buyer in respect thereof.

6.8.
Interest accruing from time to time on the balance of money standing to the
credit of the Escrow Account shall be added to the money standing to the credit
of the Escrow Account and shall form part of it for the purposes of this clause
6.

6.9.
All of the costs (including reasonable legal costs) and expenses (together with
any applicable VAT), in each case, of any nature whatsoever, of the Escrow Agent
in relation to the Escrow Account and the Escrow Agreement shall be deemed to be
Transaction Costs.

6.10.
The Escrow Agent may withdraw from the Escrow Account an amount equal to any Tax
on the interest earned in respect of money held in the Escrow Account for which
it is liable.

6.11.
On the Release Date, the money then standing to the credit of the Escrow Account
less the total of the then outstanding Disputed Business Warranty Claims and
less any amount that has not yet been paid in accordance with clause 4 or
paragraph 5 of Part A of Schedule 4 (Preparation of Completion Accounts) shall
be paid to the Payments Administrator in accordance with clause 13.1. After that
date, to the extent that the money standing to the credit of the Escrow Account
from time to time exceeds the total of the then outstanding Disputed Business
Warranty Claims and any amount that has not yet been paid in accordance with
clause 4 or paragraph 5 of Part A of Schedule 4 (Preparation of Completion
Accounts), that money shall be paid to the Payments Administrator in accordance
with clause 13.1.

6.12.
If the Sellers or the Buyer are entitled to money from the Escrow Account under
clauses 6.4 or 6.11, the Sellers’ Representative and the Buyer shall within five
(5) Business Days of the date on which the entitlement arises jointly instruct
the Escrow Agent in writing to release the money to the Payments Administrator
in accordance with clause 13.1 or the Buyer, as the case may be, together with
an amount (less any Tax and other amount the Escrow Agent is legally required to
deduct from that amount) equal to the interest actually accrued on such sum
calculated for the period from (and including) the date of this Agreement to
(but excluding) the date of payment.

6.13.
All payments made to the Buyer by the Escrow Agent under this clause 6 shall be
made gross and without deduction or withholding of any kind other than any
deduction or withholding required by law.

CONFIDENTIAL
22
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

6.14.
The amount, if any, of the Escrow Amount which is paid to the Buyer pursuant to
clause 4.2 or this clause 6 shall be treated as a reduction in the Total
Consideration.

6.15.
The Sellers agree between themselves that any amounts released to the Payments
Administrator for further distribution to the Sellers from the Escrow Account
shall be apportioned between them by reference to their respective contribution
initially made to the Escrow Amount (as set out in column F of the table in
Schedule 1 (The Sellers).

7.
SELLER WARRANTIES AND INDEMNITY

7.1.
Each Seller (i) [***] warrants [***] to the Buyer in the terms of the
Fundamental Warranties at Completion and, subject to clause 7.4, the Tax
Warranties at Completion; and (ii) subject to the limitations set forth in
Schedule 8 (Limitations on the Sellers’ Liability) agrees [***], and on a pro
rata basis in accordance with each Seller’s Proportion of Initial Consideration,
to indemnify the Buyer against any losses, costs, claims, liabilities, damages,
demands and expenses arising out of any Special Indemnity Matter save where such
losses, costs, claims, liabilities, damages, demands and/or expenses are a
result of any action or omission by or on behalf of the Buyer (or any Buyer’s
Group Undertaking) or due to the Buyer’s (or any Buyer’s Group Undertaking’s)
gross negligence, wilful misconduct or wilful concealment.

7.2.
Each Warrantor [***] warrants [***] to the Buyer in the terms of the Warrantor
Fundamental Warranties at Completion.

7.3.
Subject to clause 7.4, each Warrantor [***] warrants to the Buyer on the terms
of the Business Warranties at Completion.

7.4.
[***]. For the avoidance of doubt, [***].

7.5.
[***].

7.6.
Where [***] is qualified by the expression “so far as the Warrantors are aware”
or “to the best of the knowledge, information and belief of the Warrantors” or
qualified by any similar expression, each Warrantor shall be deemed only to have
knowledge of anything of which [***].

7.7.
Each Seller agrees and undertakes to the Buyer and to each person referred to in
this clause 7.7 that, except in the case of fraud, it will not make any claim
against the Company or any director, officer or employee of the Company on whom
it may have relied before agreeing any term of this Agreement or any of the
transaction contemplated by this Agreement which it may have in respect of a
misrepresentation, inaccuracy or omission in or from information or advice
provided by any such person for the purpose of assisting any such Seller to make
a representation, give a Warranty or prepare the Disclosure Letter (as
applicable). After

CONFIDENTIAL
23
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

Completion, the Company or any director, officer or employee of the Company may
enforce the terms of this clause 7.7 subject to and in accordance with [***].
7.8.
[***].

8.
LIMITATIONS TO THE SELLERS’ LIABILITY

8.1.
Each Seller’s liability for [***] and each Warrantor’s liability for [***] shall
be limited or excluded, as the case may be, as set out in clause 7 and Schedule
8 (Limitations on the Sellers’ Liability).

8.2.
Except as stated in this Agreement, the Buyer shall not be restricted from
including as part of any Claim any losses, costs, claims, liabilities, damages,
demands and/or expenses [***].

9.
BUYER’S WARRANTIES

The Buyer warrants to each Seller as at Completion that:
9.1.
it is a company duly incorporated and validly existing in the State of Delaware,
United States and has the right, power and authority to execute, deliver and
perform its obligations under this Agreement and any other Transactional
Document to be executed by it;

9.2.
the Buyer’s obligations under this Agreement and any other Transactional
Documents to be executed by the Buyer are, or when the relevant document is
executed will be, enforceable in accordance with their terms, subject to the
effects of bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other similar laws relating to or affecting creditors’ rights
generally and general equitable principles;

9.3.
the execution, delivery and performance by the Buyer of this Agreement and each
Transactional Document to be executed by it will not breach any provision of the
certificate of incorporation or bylaws of the Buyer or breach any applicable
laws or regulations, or any orders, judgements or decrees which the Buyer is
bound by or result in a breach of or constitute a default under any instrument,
contract or agreement to which the Buyer is a party or by which the Buyer is
bound and which, in each case, is material in the context of the transactions
contemplated by this Agreement and any of the Transactional Documents; and

9.4.
it has available on an unconditional basis (subject only to Completion) the
necessary resources to meet its obligations under this Agreement, other than
payment of the Contingent Consideration.

CONFIDENTIAL
24
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

10.
POST COMPLETION MATTERS

10.1.
Each Seller agrees in respect only of itself that the Seller shall, for so long
as the Seller remains the registered holder of any of the Relevant Shares after
Completion, hold those Relevant Shares with all rights and benefits attaching or
accruing to them on or after the date of this Agreement as bare trustee for the
Buyer absolutely.

10.2.
For a period of [***] after Completion each Seller hereby irrevocably undertakes
to the Buyer pending registration by the Company of the transfer of the Seller’s
Relevant Shares to the Buyer, to exercise any votes attaching to any of the
Seller’s Relevant Shares or sign any consent to short notice of a general
meeting (or written resolution in lieu thereof) as the Buyer may reasonably
direct.

10.3.
Each Seller acting severally shall execute and shall procure the execution of,
all documents and deeds and/or do or procure the doing of, all acts and things
that the Buyer reasonably requires after Completion to vest in the Buyer legal
title to and the full benefit of the Relevant Shares held by such Seller.

10.4.
Subject to clause 10.5, each of the Sellers (for itself and for and on behalf of
each of its Affiliates) hereby irrevocably agrees that, with effect from and
conditional upon Completion:

(a)
the Shareholder Arrangements are hereby terminated;

(b)
any and all rights of any Seller and/or any of its Affiliates and any and all
obligations of the Company under, pursuant to or in connection with the
Shareholder Arrangements, along with any other claim or demand of any Seller or
any of its Affiliates against the Company, which are subsisting or outstanding
at the date of this Agreement are expressly waived and released, including any
and all such rights and obligations, claims and demands which may have accrued
in respect of any period prior to Completion; and

(c)
any and all other debts or liabilities (whether actual, contingent or
prospective and including any interest thereon) of the Company to any Seller
under, pursuant to or in connection with the Shareholder Arrangements or
otherwise which are subsisting or outstanding at the date of this Agreement are
expressly waived, released and discharged.

10.5.
Each Seller shall ensure that at Completion there will be no amounts owing by
the Company to such Seller in respect of itself and its Affiliates only, other
than by way of accrued but unpaid salary or consultancy fees or unreimbursed
expenses incurred in the ordinary course of business consistent with past
practice owed to employees or consultants of the Company.

CONFIDENTIAL
25
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

10.6.
The Buyer shall, within 20 Business Days of Completion, procure that the name of
the Company is changed to such name as the Buyer may decide provided that it
does not include the word “F-star”.

10.7.
The Buyer intends to make an election under Section 338(g) of the United States
Internal Revenue Code of 1986, as amended (the “IRC”) (and any corresponding
election under state and local Tax law) with respect to the purchase of the
Shares under this Agreement (collectively, the “Section 338 Election”).  The
Buyer may make the Section 338 Election in its sole discretion; provided,
however, that the Sellers shall not be liable in respect of a Tax Warranty Claim
for any liability of the Company for Taxes arising directly or indirectly from
the Section 338 Election and the Buyer shall indemnify the Sellers and the
Company on an after-Tax basis against any Tax liability, losses and all
reasonable costs and expenses of the Sellers or the Company which arise directly
or indirectly as a result of the Section 338 Election being made excluding any
Tax liability, losses or costs and expenses that would have not have arisen had
all of the Tax Warranties made by the Company and Sellers been true, correct and
complete. In addition, in the case of any Seller, the calculation of any
increase in Tax liability of such Seller resulting from the Section 338 Election
shall be made assuming (a) that such Seller and any of its direct or indirect
owners has made a timely and valid election under Section 1295 of the U.S.
Internal Revenue Code of 1986, as amended (the “Code”) and the regulations
thereunder to treat its shares in the Company as a “qualified electing fund”
within the meaning of Section 1295 effective with the first day of such Seller’s
holding period in the Company’s shares and (b) that the Company is not, and has
not at any time during the five (5) taxable years preceding the Completion Date,
been a “controlled foreign corporation” within the meaning of Section 957 of the
IRC. For clarify, Purchaser shall not be required under this Section 10.7 to
indemnify the Company or any Seller for any Tax liability that would not have
arisen had a Seller (or its direct or indirect owners) elected to treat the
Company as a qualified electing fund and/or had the Company not been a
controlled foreign corporation, as described in the previous sentence.

11.
BUYER GUARANTEE

11.1.
Following Completion, the Buyer guarantees to F-star, whenever the Company does
not pay any of the Guaranteed Obligations when due, to pay within 5 Business
Days following receipt of written demand from F-star, the Guaranteed
Obligations.

11.2.
Following Completion, the Buyer as principal obligor and as a separate and
independent obligation and liability from its obligations and liabilities under
clause 11.1 agrees to indemnify and keep indemnified F-star in full and on
written demand from and against all and any losses, costs, claims, liabilities,
damages, demands and expenses suffered or incurred by F-star arising directly
out of the Guaranteed Obligations not being recoverable for any

CONFIDENTIAL
26
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

reason or any failure of the Company to pay any of its obligations or
liabilities in respect of the Guaranteed Obligations.
11.3.
This guarantee is and shall cover the ultimate balance from time to time owing
to F-star by the Company in respect of the Guaranteed Obligations.

11.4.
The liability of the Buyer under this clause 11 shall not be terminated by:

(a)
any intermediate payment, settlement of account or discharge in part of the
Guaranteed Obligations;

(b)
any variation, extension, discharge, compromise, dealing with, exchange or
renewal of any right or remedy which F-star may now or after the date of this
guarantee have from or against any of the Company and any other person in
connection with the Guaranteed Obligations;

(c)
any amendment, variation, novation, replacement or supplement of or to any of
the Guaranteed Obligations;

(d)
any grant of time, indulgence, waiver or concession to the Company or any other
person;

(e)
any insolvency, bankruptcy, liquidation, administration, winding up, incapacity,
limitation, disability, the discharge by operation of law, or any change in the
constitution, name or style of the Company, F-star, or any other person;

(f)
any claim or enforcement of payment from the Company or any other person; or

(g)
any act or omission which would not have discharged or affected the liability of
the Buyer had it been a principal debtor instead of a guarantor, or indemnifier
or by anything done or omitted by any person which, but for this provision,
might operate to exonerate or discharge the Buyer or otherwise reduce or
extinguish its liability under this guarantee.

11.5.
Any release, discharge or settlement between the Buyer and F-star in relation to
this guarantee shall be conditional on no right, disposition or payment to
F-star by the Buyer, the Company or any other person in respect of the
Guaranteed Obligations being avoided, set aside or ordered to be refunded under
any enactment or law relating to breach of duty by any person, bankruptcy,
liquidation, administration, protection from creditors generally or insolvency
or for any other reason.

11.6.
If any right, disposition or payment referred to in clause 11.5 is avoided, set
aside or ordered to be refunded, F-star shall be entitled subsequently to
enforce this guarantee against the

CONFIDENTIAL
27
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

Buyer as if such release, discharge or settlement had not occurred and any such
right, security, disposition or payment had not been given or made.
11.7.
F-star shall be entitled to enforce this clause 11 against the Buyer as if it
were a party to this Agreement.

12.
SELLERS’ REPRESENTATIVE

12.1.
Each Seller hereby irrevocably and unconditionally appoints the Sellers’
Representative as sole representative agent and attorney-in-fact to act on such
Seller’s behalf for all purposes relating to this Agreement after Completion and
each agreement and document ancillary thereto, including for the purposes of:

(a)
accepting and giving notices on behalf of such Seller;

(b)
making elections and granting any consent or approval on behalf of such Seller
under this Agreement;

(c)
approving and executing any document on behalf of such Seller to give effect to
the release of any money then standing to the credit of the Escrow Account;

(d)
defending, negotiating, compromising, settling and releasing on behalf of such
Seller any rights and claims (including legal proceedings) which the Buyer may
threaten or pursue in respect of any breach of, or right under, this Agreement
or any other Transactional Document;

(e)
confirming the allocation between the Sellers of the Contingent Consideration to
be made under this Agreement;

(f)
enforcing, negotiating, compromising, settling and releasing on behalf of such
Seller any rights and claims (including legal proceedings and ADR) which he may
have, threaten or pursue against the Buyer (or any other person) in respect of
any breach of, or right under, this Agreement or any other Transactional
Document or any Dispute;

(g)
consent or agree to any amendment to this Agreement or to waive any terms and
conditions of this Agreement providing rights or benefits to the Sellers (other
than with respect to the payment of the Total Consideration) in accordance with
the terms hereof and in the manner provided herein;

(h)
taking any and all actions that may be necessary or desirable in connection with
the payment by the Sellers of the costs and expenses incurred under this
Agreement; and

CONFIDENTIAL
28
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

(i)
generally taking any and all other actions and doing any and all other things
provided in or contemplated by this Agreement and each agreement and document
ancillary thereto to be performed by such Seller or the Sellers’ Representative.

12.2.
Each Seller hereby irrevocably (by way of security for the performance of his
obligations under this Agreement) appoints the Sellers’ Representative as its
agent with full authority on his behalf and in the Seller’s name, as applicable,
or otherwise, to do all acts and to execute and deliver such documents or deeds
as are required by law or as may, in the reasonable opinion of the Sellers’
Representative, be required or convenient to give effect to the matters
described in clause 12.1.

12.3.
The Sellers’ Representative shall act in good faith in accordance with what the
Sellers’ Representative believes to be the best interests of the Sellers when
exercising any power or authority conferred on under this clause 12.

12.4.
Save in the event of fraud, any action undertaken or omitted by the Sellers’
Representative with the written approval of a Sellers’ Majority shall be
conclusively deemed to be in accordance with the requirements of clause 12.3
provided that, for the avoidance of doubt, such approval shall not be necessary.

12.5.
The Sellers’ Representative may resign at any time. The Sellers’ Representative
may consult with any Seller to the extent a claim is threatened or pursued by
the Buyer in respect of any breach of, or right under, this Agreement or any
other Transactional Document and which specifically concerns any actual or
alleged act or default of that Seller.

12.6.
The Sellers may, by written notice signed by a Sellers Majority (a “Change Of
Sellers’ Representative Notice”), replace a resigning Sellers’ Representative or
remove an incumbent Sellers’ Representative from such position and appoint
another person to act as Sellers’ Representative in substitution thereof (a “New
Sellers’ Representative”). A Change Of Sellers’ Representative Notice shall be
effective only once a copy thereof has been served on both the incumbent
Sellers’ Representative and the Buyer.

12.7.
A New Sellers’ Representative so appointed shall, with effect from the time of
its appointment, execute a deed of adherence in favour of the Sellers and the
Buyer pursuant to which it shall agree to adhere to, and be bound by, this
Agreement as though named herein as the Sellers’ Representative and the parties
agree that such substitute New Sellers’ Representative shall be conferred the
rights, power and authorities (including as set out in this clause 12) of the
Sellers’ Representative as set out in this Agreement and entitled to directly
enforce the same (notwithstanding that it may not have initially been a
signatory hereto). A copy of such deed of adherence shall be delivered to the
Buyer at the same time as the Change Of Sellers’ Representative Notice is served
thereon under clause 12.6.

CONFIDENTIAL
29
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

12.8.
If at any time a New Sellers’ Representative is appointed in accordance with
clause 12.6, if required by the Buyer, the Sellers’ Representative hereby
undertakes to do all such things as may be necessary to novate the Escrow
Agreement from the previous Sellers’ Representative to the New Sellers’
Representative.

12.9.
Any action taken or any exercise of powers under this Agreement by the Sellers’
Representative or any New Sellers’ Representative shall be binding on each
Seller for the purposes of this Agreement, shall be deemed to be done by each
Seller, and the Buyer shall be entitled to assume that any action taken by the
Sellers’ Representative or any New Sellers’ Representative whose appointment has
been notified in accordance with this clause 14 is binding on all of the Sellers
and the parties shall be entitled to rely on the same. The Buyer shall not be
required to make further enquiries in respect thereof. The Buyer shall have no
obligation to monitor or supervise the Sellers’ Representative or any New
Sellers’ Representative. The Buyer shall not be liable to any of the Sellers for
any action taken or omitted to be taken by the Sellers’ Representative or any
New Sellers’ Representative.

12.10.
All costs (including legal costs) and expenses (including Tax), in each case, of
any nature whatsoever, of the Sellers’ Representative shall be borne by the
Sellers in the proportions set out in column D of the table in Schedule 1 (The
Sellers).

12.11.
The Sellers’ Representative shall have no liability or obligation to take any
action on behalf of any Seller under the powers and authorities conferred on the
Sellers’ Representative by this Agreement where such action may result in the
Sellers’ Representative incurring any cost, expense or liability unless the
Sellers’ Representative is satisfied with any arrangements made by (or on behalf
of) the Sellers for the satisfaction or re-imbursement of such costs, expenses
and liabilities.

12.12.
Upon Completion, and subject to receipt by the Sellers’ Representative of the
cash sum provided for in clause 3.3(a), the Sellers’ Representative will retain
an amount of [***] from such sum (the “Expense Fund”), which will be used for
the purposes of paying directly, or reimbursing the Sellers’ Representative for,
any third party expenses pursuant to this Agreement and the transactions
contemplated hereby. The Sellers will not receive any interest or earnings on
the Expense Fund and irrevocably transfer and assign to the Sellers’
Representative any ownership right that they may otherwise have had in any such
interest or earnings. The Sellers’ Representative will not be liable for any
loss of principal of the Expense Fund other than as a result of its gross
negligence or wilful misconduct. The Sellers’ Representative will hold these
funds separate from its corporate funds in a segregated client account, will not
use these funds for its operating expenses or any other corporate purposes and
will not voluntarily make these funds available to its creditors in the event of
bankruptcy. As soon as practicable following the completion of the Sellers’
Representative’s responsibilities, the Sellers’ Representative will distribute
the balance of the Expense Fund

CONFIDENTIAL
30
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

to the Payments Administrator for further distribution to the Sellers. For tax
purposes, the Expense Fund shall be treated as having been received and
voluntarily set aside by the Sellers at the time of Completion. The parties
agree that the Sellers’ Representative is not responsible for any tax
withholding or reporting or acting as a withholding agent or in any similar
capacity in connection with the Expense Fund.
12.13.
The Sellers’ Representative will incur no liability of any kind with respect to
any action or omission by the Sellers’ Representative in connection with
Sellers’ Representative’s services pursuant to this Agreement and any agreements
ancillary hereto, except in the event of liability directly resulting from the
Sellers’ Representative’s gross negligence or wilful misconduct. The Sellers’
Representative shall not be liable to any Seller as a result of any action or
omission that is taken (or not taken) in good faith pursuant to the advice of
external legal counsel in the proper performance of its obligations under this
Agreement. The Sellers will, severally and not jointly, on a pro rata basis
equal to the portion of Total Consideration each such Seller is entitled to
receive pursuant to this Agreement compared to the aggregate Total Consideration
entitled to be received by all Sellers, indemnify, defend and hold harmless the
Sellers’ Representative from and against any and all losses, liabilities,
damages, claims, penalties, fines, forfeitures, actions, fees, costs and
expenses (including the fees and expenses of counsel and experts and their
staffs and all expense of document location, duplication and shipment)
(collectively, “Representative Losses”) arising out of or in connection with the
Sellers’ Representative’s execution and performance of this Agreement and any
agreements ancillary hereto, in each case as such Representative Loss is
suffered or incurred; provided, that in the event that any such Representative
Loss is finally adjudicated to have been directly caused by the gross negligence
or wilful misconduct of the Sellers’ Representative, the Sellers’ Representative
will reimburse the Sellers the amount of such Representative Loss to the extent
attributable to such gross negligence or wilful misconduct. If not paid directly
to the Sellers’ Representative by the Sellers, any such indemnified
Representative Losses may be recovered by the Sellers’ Representative from (i)
the funds in the Expense Fund, (ii) the amounts in the Escrow Amount at such
time as remaining amounts would otherwise be distributable to the Sellers, and
(iii) from any Milestone Payments at such time as any such amounts would
otherwise be distributable to the Sellers; provided, that while this section
allows the Sellers’ Representative to be paid from the Expense Fund, the Escrow
Amount and the Milestone Payments, this does not relieve the Sellers from their
obligation to promptly pay such Representative Losses as they are suffered or
incurred, nor does it prevent the Sellers’ Representative from seeking any
remedies available to it at law or otherwise. In no event will the Sellers’
Representative be required to advance its own funds on behalf of the Sellers or
otherwise. For the avoidance of doubt and notwithstanding anything in this
Agreement to the contrary, the limitations on liability of the Sellers set forth
elsewhere in this Agreement are not intended to be applicable

CONFIDENTIAL
31
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

to the indemnities provide to the Sellers’ Representative under this clause
12.13. The Sellers acknowledge and agree that the foregoing indemnities will
survive the resignation or removal of the Sellers’ Representative or the
termination of this Agreement.

13.
PAYMENTS

13.1.
Payments to be made to the Sellers under this Agreement shall be made in US
dollars by telegraphic transfer of immediately available funds to such account
controlled by the Payments Administrator as may be notified by the Payments
Administrator or the Sellers’ Representative in writing to the Buyer.

13.2.
Payments to be made to the Buyer under this Agreement shall be made in US
dollars by telegraphic transfer of immediately available funds to such account
as may be notified in writing by the Buyer to the Payments Administrator.

13.3.
The payment of any sum to the Buyer by or on behalf of any of the Sellers will
discharge the obligations of the Sellers to pay the sum in question and the
Sellers shall not be concerned to see the application of the monies so paid.

13.4.
The payment of any sum to the Payments Administrator by or on behalf of the
Buyer will discharge the obligations of the Buyer to pay the sum in question and
the Buyer shall not be concerned to see the application of the monies so paid.

14.
ANNOUNCEMENTS

14.1.
Subject to clause 14.2, no party (the “disclosing party”) may, before or after
Completion, make or issue a public announcement or press release concerning the
transactions referred to in this Agreement other than the Press Release unless
it has first obtained the written consent of the Sellers (prior to Completion,
if the disclosing party is the Buyer) or the Sellers’ Representative (after
Completion, if the disclosing party is the Buyer), or of the Buyer (if the
disclosing party is a Seller) (in either case, the “other party”), which consent
may not be unreasonably withheld or delayed.

14.2.
Clause 14.1 does not apply to a public announcement or press release required by
law, by a rule of a listing authority by which a party’s shares are listed, a
stock exchange on which a party’s shares are listed or traded or by a
governmental authority or other authority with relevant powers to which either
party is subject or submits, whether or not the requirement has the force of
law, provided that the public announcement, communication or circular shall so
far as is practicable be made after consultation with the other party and after
taking into account the reasonable requirements of the other party as to its
timing, content and manner of making or despatch.

CONFIDENTIAL
32
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

15.
CONFIDENTIALITY

15.1.
Subject to clause 15.4, each party shall treat the following information as
confidential to the extent obtained as a result of or in connection with
entering into this Agreement:

(a)
details of the provisions of this Agreement, the Transactional Documents and any
other agreement or arrangement entered into in connection with this Agreement;

(b)
information relating to the negotiations leading to the execution of this
Agreement, the Transactional Documents and any other agreement or arrangement
entered into in connection with this Agreement; and

(c)
(to the extent obtained as a result of or in connection with entering into this
Agreement) information relating to the other party or such party’s group
undertakings,

provided that the parties shall always be permitted to confirm that the
transaction effected by this Agreement has taken place without providing any
further information.
15.2.
Any party may disclose information otherwise required by clause 15.1 to be
treated as confidential:

(a)
if and to the extent required by the laws of any relevant jurisdiction, provided
that the disclosing party shall, where it is practicable to do so and where
permitted under applicable law, notify the other party of such disclosure in
writing and take reasonable steps to minimize the extent of any such required
disclosure;

(b)
if and to the extent requested by any competent regulatory or governmental body,
Tax Authority or securities exchange in any relevant jurisdiction wherever
situated, whether or not the request has the force of law and including for the
avoidance of doubt, any disclosure required by US accounting regulations;

(c)
to a Tax Authority in connection with the Tax affairs of the disclosing party;

(d)
to its professional advisers, auditors or bankers from time to time provided
that such disclosure is reasonably required;

(e)
to its shareholders and/or its limited partners as appropriate;

(f)
in the case of the Buyer, to members of the Buyer’s Group and to their
professional advisers, auditors or bankers in each case from time to time;

(g)
if and to the extent the information is or comes into the public domain through
no fault of that part of any of those to whom that party has disclosed
information; or

CONFIDENTIAL
33
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

(h)
if and to the extent, in the case of a Seller, the Buyer or, in the case of the
Buyer, the Sellers’ Representative, has given prior written consent to the
disclosure.

15.3.
Each party shall ensure that any person to whom confidential information is
disclosed pursuant to clauses 15.2(d) through 15.2(f) is made aware of the
obligations of confidentiality contained in this clause and agrees to adhere to
them.

15.4.
Notwithstanding anything in this Agreement to the contrary, following
Completion, the Sellers’ Representative shall be permitted to: (i) after the
public announcement (if any) of the transaction contemplated by this Agreement,
publicly announce that it has been engaged to serve as the Sellers’
Representative in connection with the transaction as long as such announcement
does not disclose any of the other terms hereof and (ii) disclose information to
the Sellers who have a need to know such information provided that any such
information will be subject to the confidentiality provisions of this Agreement
including clause 15.1.

16.
COSTS

Except where this Agreement or the relevant document provides otherwise, each
party shall pay its own costs relating to the negotiation, preparation,
execution and performance by it of this Agreement and of each document referred
to in it.

17.
GENERAL

17.1.
A variation of this Agreement is valid only if it is in writing and signed by or
on behalf of each party, provided that after Completion, any variation may be
signed by the Sellers’ Representative on behalf of itself and the Sellers
provided the Sellers’ Representative has the prior written approval of the
Sellers Majority. The parties to this Agreement do not require the consent of
any person having a right under the Contracts (Rights of Third Parties) Act
1999, as provided in clause 17.7, to rescind or vary this agreement.

17.2.
The failure to exercise or delay in exercising a right or remedy provided by
this Agreement or by law does not impair or constitute a waiver of the right or
remedy or an impairment of or a waiver of other rights or remedies. No single or
partial exercise of a right or remedy provided by this Agreement or by law
prevents further exercise of the right or remedy or the exercise of another
right or remedy.

17.3.
The Buyer’s rights and remedies contained in this Agreement are cumulative and
not exclusive of rights or remedies provided by law to the extent not excluded
or limited by this Agreement.

17.4.
Except to the extent that they have been performed and except where this
Agreement provides otherwise, the obligations contained in this Agreement remain
in force after Completion.

CONFIDENTIAL
34
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

17.5.
Any payment by a Seller, pursuant to a Fundamental Warranty Claim, Special
Indemnity Claim or Tax Warranty Claim or a Warrantor, pursuant to a Warrantor
Fundamental Warranty Claim or a Business Warranty Claim shall, to the extent
possible and without limiting the liability of any Seller or Warrantor (as the
case may be) under this Agreement, be treated as a reduction in the purchase
price payable by the Buyer for the Shares.

17.6.
All payments made by a Seller under this Agreement shall be made gross, free of
right of counterclaim or set off and without deduction or withholding of any
kind other than deductions or withholding required by law.

17.7.
Except as provided in clauses 10.7 and 11.7, a person who is not a party to this
Agreement has no right, including under the Contracts (Rights of Third Parties)
Act 1999 to enforce any term of this Agreement.

18.
ENTIRE AGREEMENT

18.1.
The Transactional Documents constitute the entire agreement between the parties.
They supersede any previous agreements relating to the subject matter of the
Transactional Documents, and set out the complete legal relationship of the
parties arising from or connected with that subject matter.

18.2.
Nothing in this clause 19 shall have the effect of limiting any liability
arising from fraud or wilful non-disclosure.

19.
ASSIGNMENT

19.1.
Subject to clause 19.2, no right or obligation arising under this Agreement or
any other Transactional Document may be assigned, transferred or otherwise
disposed of, in whole or in part without the prior written agreement if the
assignor is the Buyer, of the Sellers’ Representative, or if the assignor is a
Seller, of the Buyer.

19.2.
The Buyer shall be entitled to assign any benefit arising under or out of this
Agreement or any other Transactional Document to any Buyer’s Group Undertaking
provided that the Buyer enters into a guarantee in a form reasonably
satisfactory to the Sellers’ Representative and further provided that, if the
assignee is to cease to be a Buyer’s Group Undertaking it shall, before ceasing
to be so, assign the benefit (so far as it is assigned) to another Buyer’s Group
Undertaking.

19.3.
The Buyer agrees that if it makes an assignment pursuant to this clause 19, the
assignment shall not increase the liabilities of any Seller.

CONFIDENTIAL
35
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

20.
NOTICES

20.1.
A notice or other communication under or in connection with this Agreement (a
“Notice”) shall be:

(a)
in writing;

(b)
in the English language; and

(c)
delivered personally or sent by first class post (and air mail if overseas) or
fax or email to the party due to receive the Notice to the address set out in
clause 20.3 or to an alternative address, person or fax number or email address
specified by that party by not less than five Business Days’ written notice to
the other party received before the Notice was despatched.

20.2.
Unless there is evidence that it was received earlier, a Notice is deemed given
if:

(a)
delivered personally, when left at the address referred to in clause 20.3;

(b)
sent by mail, except air mail, two Business Days after posting it;

(c)
sent by air mail, six Business Days after posting it; and

(d)
sent by email, when the email is sent, provided that a copy of the Notice is
sent by another method referred to in this clause 20.2 on the same Business Day
as the sending of the email, and provided further that the sender of the email
does not receive an automated response from the recipient or a mail server
indicating that the recipient is out of office or that the email could not be
delivered.

20.3.
The address referred to in clause 23.1.3 is:

CONFIDENTIAL
36
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

Name of Party
Address
Email address or telephone number
For the attention of
 
 
 
 
Each Seller
In relation to each Seller, the address set out adjacent to that Seller’s name
in column A of Schedule 1 (The Sellers).
 
 
 
 
Seller's Representative
Shareholder Representative Services LLC
1614 15th Street, Suite 200, Denver, CO 80202, United States
deals@srsacquiom.com
Managing Director
 
 
 
 
The Buyer
201 Gateway Boulevard
South San Francisco
California
United States
[***]
Nick Galli and Alexander Schuth
 
 
 
 

21.
COUNTERPARTS

This Agreement may be executed in any number of counterparts, each of which when
executed and delivered is an original and all of which together evidence the
same agreement.

22.
GOVERNING LAW

This Agreement or the performance, enforcement, breach or termination hereof
shall be interpreted, governed by and construed in accordance with the laws of
England, excluding any conflicts or choice of law rule or principle that might
otherwise refer construction or interpretation of this Agreement to the
substantive law of another jurisdiction.

23.
DISPUTE RESOLUTION

23.1.
If a dispute arises between the Parties in connection with or relating to this
Agreement or any document or instrument delivered in connection herewith (a
“Dispute”), it shall be resolved pursuant to this clause 23.

23.2.
General

Any Dispute shall first be referred to the Chief Executive Officer of the Buyer
and the Sellers’ Representative, who shall confer in good faith on the
resolution of the issue. Any final decision mutually agreed to by such persons
shall be conclusive and binding on the parties to this Agreement. If such
persons are not able to agree on the resolution of any such

CONFIDENTIAL
37
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

issue within thirty (30) days (or such other period of time as mutually agreed
by the Buyer and the Seller’s Representative) after such issue was first
referred to them, then either the Buyer or the Sellers’ Representative may, by
written notice to the other, elect to initiate an alternative dispute resolution
(“ADR”) proceeding pursuant to the procedures set forth in clause 23.3 for
purposes of having the matter settled.
23.3.
ADR

Any ADR proceeding under this Agreement (with the exception of that specified in
paragraph 11 of Schedule 8) shall take place pursuant to the procedures set
forth in clause 15.7.3 of the License Agreement, save that references to
“Denali” are references to the Buyer and references to the “Licensor” are
references to the Sellers (or relevant Seller).
23.4.
Interim Relief

Notwithstanding anything herein to the contrary, nothing in this clause 23 shall
preclude either party from seeking interim or provisional relief, including a
temporary restraining order, preliminary injunction or other interim equitable
relief concerning a Dispute following the ADR procedures set forth in clause
23.3, if necessary to protect the interests of such party. This clause shall be
specifically enforceable.
23.5.
RIGHTS OF EACH PARTY/NON-WAIVER

The rights of each party under this Agreement:
(a)
may be exercised as often as necessary;

(b)
except as otherwise expressly provided in this Agreement, are cumulative and not
exclusive of rights and remedies provided by law; and

(c)
may be waived only in writing and specifically.

24.
PROCESS AGENTS

The Buyer irrevocably appoints [***] as its process agent to receive on its
behalf service of process in any proceedings [***]. Service upon the process
agent shall constitute good and valid service on the Buyer whether or not the
process is forwarded to or received by the Buyer. If for any reason the process
agent ceases to act as process agent, resigns [***], the Buyer irrevocably
agrees to appoint a substitute process agent [***] acceptable to the Sellers’
Representative and to deliver to the Sellers’ Representative a copy of the
substitute process agents’ acceptance of that appointment within 10 Business
Days of the obligation to appoint arising. In the event that the Buyer fails to
appoint a substitute process agent, it shall be

CONFIDENTIAL
38
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

effective service for the Sellers (or the Sellers’ Representative) to serve
process upon the last known address [***] of the last known process agent for
the Buyer notified to the Sellers, notwithstanding that such process agent is no
longer found at such address or has ceased to act.

25.
CONFLICT WAIVER

Notwithstanding that the Company has been represented by Cooley (UK) LLP (the
“Firm”) in the preparation, negotiation and execution of this Agreement and the
transactions contemplated hereby, the Company agrees that after Completion the
Firm may represent the Sellers’ Representative, the Sellers and/or their
Affiliates in matters related to this Agreement and the transactions
contemplated hereby, including without limitation in respect of any
indemnification claims pursuant to this Agreement and the transactions
contemplated hereby. The Company hereby acknowledges, on behalf of itself and
its Affiliates, that it has had an opportunity to ask for and has obtained
information relevant to such representation, including disclosure of the
reasonably foreseeable adverse consequences of such representation, and it
hereby waives any conflict arising out of such future representation.
IT WITNESS whereof this Agreement has been entered into as a deed and is
delivered on the date first aforementioned.

CONFIDENTIAL
39
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

SCHEDULE 1
The Sellers
(A)
(B)
(C)
(D)
(E)
(F)
Name and Address of Seller
No. of Ordinary Shares
No. of Deferred Shares
Proportion of Initial Consideration (%)
Contribution to Expense Fund (US$)
Contribution to Escrow Account (%)
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]

[***] 

CONFIDENTIAL
40
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

SCHEDULE 2
Information about the Company
Registered Number:
10214672
 
 
Place of Incorporation:
England and Wales
 
 
Address of Registered Office:
Eddeva B920
Babraham Research Campus
Cambridge CB22 3AT
 
 
Type of Company:
Private company limited by shares
 
 
Total Issued Share Capital:
£90.39625 comprising (i) 8,969,550 ordinary shares; and (ii) 70,075 deferred
shares, in each case with an aggregate nominal value of £0.00001 with £0.00001
paid up on each share
 
 
Directors:
John Edwards
Jean-Francois Formela
Deborah Harland
Tolga Hassan
John Haurum
Patrick Krol
Florian Ruker
Helmut Schuehsler
 
 
Secretary:
Tolga Hassan
 
 
Accounting Reference Date:
31 December
 
 
Subsidiaries:
None

CONFIDENTIAL
41
 

--------------------------------------------------------------------------------

SCHEDULE 3
Completion Requirements
1.
Sellers’ Obligations

1.1.
At Completion, each Seller shall deliver the following documents or items to the
Buyer or at the Buyer’s direction:

1.1.1.
duly executed transfer(s) in respect of that Seller’s Relevant Shares to the
Buyer or its nominee(s) and the share certificate(s) for such Relevant Shares;

1.1.2.
duly executed powers of attorney or other authorities in the agreed form under
which this Agreement, the other Transactional Documents and the transfers
referred to in paragraph 1.1.1 of this Schedule 3 have been or are to be
executed by such Seller; and

1.1.3.
(if the Buyer so requires) an irrevocable power of attorney in the agreed form
duly executed by such Seller and any other registered owner of such Seller’s
Relevant Shares in favour of the Buyer or its nominee(s) generally in respect of
the Relevant Shares.

1.2.
At Completion the Sellers shall deliver, procure delivery or make available to
the Buyer:

1.2.1.
each register, minute book and other book required by law to be kept by the
Company made up to the Completion Date and each certificate of incorporation and
certificate(s) of incorporation on change of name for the Company;

1.2.2.
(if the Buyer so requires) resignations in the agreed form from each director
and secretary of the Company expressed to take effect from the end of the
meeting held pursuant to paragraph 1.3;

1.2.3.
the Management Accounts;

1.2.4.
a copy of each bank mandate of the Company and copies of statements of each bank
account of the Company made up to a date not earlier than two (2) Business Days
before the Completion Date;

1.2.5.
a counterpart of the Escrow Agreement duly executed by the Sellers’
Representative; and

1.2.6.
the Disclosure Letter signed on behalf of each Warrantor.

CONFIDENTIAL
42
 

--------------------------------------------------------------------------------

1.3.
The Sellers shall ensure that at Completion a meeting of the board of directors
of the Company is held at which the directors:

1.3.1.
vote in favour of the registration of the Buyer or its nominee(s) as member(s)
of the Company in respect of the Shares (subject to the production of properly
stamped transfers); and

1.3.2.
approve the payment of the Transaction Costs.

2.
Buyer’s Obligations

2.1.
At Completion, the Buyer shall deliver to the Sellers:

2.1.1.
a counterpart of the Escrow Agreement duly executed by the Buyer; and

2.1.2.
a counterpart of the Disclosure Letter signed by the Buyer.

2.2.
At Completion, the Buyer shall procure that the Company shall pay the
Transaction Costs to the extent not already paid.

CONFIDENTIAL
43
 

--------------------------------------------------------------------------------

SCHEDULE 4
Completion Accounts
Part A: Preparation of Completion Accounts
1.
The Buyer shall procure that Draft Completion Accounts are prepared in
accordance with the provisions of this Part A of Schedule 4 and on the basis of
the Accounting Policies.

2.
The Draft Completion Accounts shall be delivered to the Sellers’ Representative
by the Buyer as soon as is reasonably practicable and, in any event, not later
than 90 calendar days after Completion.

3.
If the Sellers’ Representative does not within 30 calendar days of presentation
to it of the Draft Completion Accounts give notice to the Buyer that it
disagrees with the Draft Completion Accounts or any item therein, stating the
reasons for the disagreement in reasonable detail including each disputed item,
the amount in dispute and the basis for such dispute (the “Sellers’ Disagreement
Notice”), the Draft Completion Accounts shall constitute the Completion Accounts
and shall be final and binding on the parties for all purposes in accordance
with paragraph 12 of this Part A of Schedule 4.

4.
If the Sellers’ Representative gives a Sellers’ Disagreement Notice under
paragraph 3, the Buyer and the Sellers’ Representative shall attempt in good
faith to reach agreement in respect thereof (and, if such agreement is reached,
the Draft Completion Accounts as amended by the matters set out in the Sellers’
Disagreement Notice and agreed by the Buyer and the Sellers’ Representative in
writing shall constitute the Completion Accounts and shall be final and binding
on them for all purposes in accordance with paragraph 12 of this Part A of
Schedule 4). If they are unable to do so within 30 calendar days of such
notification under paragraph 3 of this Part A of Schedule 4, either party may,
by notice to the other (an “Appointment Notice”), require that the Draft
Completion Accounts be referred to an independent firm of internationally
recognised chartered accountants agreed upon by the Buyer and the Sellers’
Representative or, failing agreement within five (5) Business Days of service of
the Appointment Notice, nominated by the President for the time being of the
Institute of Chartered Accountants in England and Wales or in his/her absence a
suitable deputy (the “Reporting Accountants”).

5.
The Reporting Accountants shall be engaged jointly by the Buyer and the Sellers
(acting through the Sellers’ Representative) and the charges (including any VAT)
of the Reporting Accountants shall be allocated between the Buyer on the one
hand and the Sellers (acting through the Sellers’ Representative) on the other
by the Reporting Accountants in proportion

CONFIDENTIAL
44
 

--------------------------------------------------------------------------------

to the extent either of such parties did not prevail in the aggregate on the
disputed items (as measured by the amounts in dispute). If any amount is payable
by the Sellers pursuant to this paragraph 5, such amount shall be paid from the
Escrow Account when the Buyer and the Sellers’ Representative shall within three
(3) Business Days following the date of such election or within five (5)
Business Days of the Determination Date (whichever is later) jointly instruct
the Escrow Agent in writing to make such payment out of amounts standing to the
credit of the Escrow Account.
6.
Except to the extent that the Buyer and the Sellers’ Representative agree
otherwise, the Reporting Accountants shall determine their own procedure but
each party shall use all reasonable endeavours to procure that the Reporting
Accountants apply the following rules:

6.1.
apart from procedural matters and as otherwise set out in this Agreement, they
shall determine only:

6.1.1.
whether any of the arguments for an alteration to the Draft Completion Accounts
put forward in respect of matters specified in the Sellers’ Disagreement Notice
is correct in whole or in part (unless such matters have been agreed between the
Sellers’ Representative and the Buyer); and

6.1.2.
if so, what alterations (if any) should be made to the Draft Completion
Accounts;

6.2.
they shall apply the Accounting Policies;

6.3.
they shall make their determination pursuant to paragraph 6.1 of this Part A of
Schedule 4 as soon as is reasonably practicable;

6.4.
the procedure of the Reporting Accountants shall:

6.4.1.
give the Buyer and the Sellers’ Representative a reasonable opportunity to make
oral representations and representations in writing to them;

6.4.2.
require that each party supplies the other with a copy of any representations in
writing at the same time as they are made to the Reporting Accountants; and

6.4.3.
permit each party to be present while oral submissions are being made by the
other party;

6.5.
for the avoidance of doubt, the Reporting Accountants shall not be entitled to
determine the scope of their own jurisdiction; and

6.6.
the determination of the Reporting Accountants pursuant to paragraph 6.1 of this
Part A of Schedule 4 shall be made in writing.

CONFIDENTIAL
45
 

--------------------------------------------------------------------------------

7.
The Reporting Accountants shall act as experts and not as arbitrators and their
determination of any matter falling within their jurisdiction shall be final and
binding on the parties, save in the event of fraud of the Buyer, any of the
Sellers or the Reporting Accountants or manifest error of the Reporting
Accountants (when the relevant part of their determination shall be void). In
particular, without limitation, their determination shall be deemed to be
incorporated into the Draft Completion Accounts, which shall then be final and
binding on the parties for the purposes of this Schedule 4, save as stated above
in the event of fraud or manifest error.

8.
The Buyer and the Sellers’ Representative shall co-operate with the Reporting
Accountants and comply with their reasonable requests made in connection with
the carrying out of their duties pursuant to their engagement under the terms of
this Agreement.

9.
Subject to paragraph 10 of this Part A of Schedule 4, nothing in this Schedule 4
shall entitle the Buyer or the Sellers’ Representative or the Reporting
Accountants to have access to any information or document which is protected by
legal professional privilege, or which has been prepared by the other party or
its accountants or other professional advisers with a view to assessing the
merits of any claim or argument.

10.
The Buyer and the Sellers’ Representative shall not be entitled by reason of
paragraph 9 of this Part A of Schedule 4 to refuse to supply such part or parts
of documents as contain only the facts on which the relevant claim or argument
is based.

11.
Each party and the Reporting Accountants shall, and shall procure that its
accountants and other advisers shall, keep all information and documents
provided to them pursuant to this Part A of Schedule 4 confidential and shall
not use them for any purpose, except for disclosure or use in connection with
the preparation of the Draft Completion Accounts and the agreement or
determination of the Completion Accounts, the proceedings of the Reporting
Accountants or any other matter arising out of this Agreement or in defending
any claim or argument or alleged claim or argument relating to this Agreement or
its subject matter.

12.
When the Sellers’ Representative and the Buyer reach agreement on the Draft
Completion Accounts or when the Draft Completion Accounts is finally determined
at any stage in accordance with the procedures set out in this Part A of
Schedule 4:

12.1.
the Draft Completion Accounts as so agreed or determined shall constitute the
Completion Accounts for the purposes of this Agreement and shall (in the absence
of fraud or manifest error) be final and binding on the parties; and

12.2.
the “Actual Net Cash” shall be the amount set out in line item “E” in the
Completion Accounts.

CONFIDENTIAL
46
 

--------------------------------------------------------------------------------

13.
Subject to paragraph 9 of this Part A of Schedule 4 and clause 15 of the
Agreement, each Seller shall (in relation to information in its possession or
control only) and the Buyer shall procure that the Company shall (in relation to
information in their respective possession or control), promptly provide the
parties, their respective advisers, the Buyer’s accountants and the Sellers’
accountants and, if relevant, the Reporting Accountants with all information (in
their respective possession or control) relating to the operations of the
Company, as the case may be, including access at all reasonable times to the
Company and the employees of the Company (who shall give such explanations as
any party may reasonably require in relation to the preparation of the Draft
Completion Accounts), books, records, and other relevant information and all
cooperation and assistance, as in any such case be reasonably required to enable
the production and agreement or determination of the Completion Accounts
pursuant to and in accordance with this Part A of Schedule 4; provided however,
that the auditors or accountants of the Buyer or the Company shall not be
obliged to make any work papers available to any person unless and until such
person has signed a customary agreement relating to access to such work papers
in form and substance reasonably acceptable to the Buyer and such auditors or
accountants.

14.
The Sellers (acting through the Seller’s Representative) and the Buyer shall
each bear their own costs (including legal costs) and expenses (including tax)
together with VAT charged thereon, arising out of the preparation and review of
the Draft Completion Accounts and the agreement or determination of the
Completion Accounts.

CONFIDENTIAL
47
 

--------------------------------------------------------------------------------

Part B: Completion Accounts

 
 
[***]
 
[***]
 
[***]
[***]
 
[***]
[***]
 
[***]
[***]
 
[***]
[***]
 
[***]
[***]
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
48
 

--------------------------------------------------------------------------------

Part C: Accounting Policies
1.
General Accounting Policies

1.1.
The Completion Accounts shall be determined in accordance with the following:

(a)
first, in accordance with the [***];

(b)
secondly, and to the extent not covered by or inconsistent with paragraph 1.1(a)
of this Part C of Schedule 4 (which shall prevail in the event of any
inconsistency), on a basis consistent with [***]; and

(c)
thirdly, and to the extent not covered by or inconsistent with paragraphs 1.1(a)
or 1.1(b) of this Part C of Schedule 4 (which shall prevail in the event of any
inconsistency), [***].

1.2.
The parties acknowledge that the sole purpose of determining the Actual Net Cash
is to determine the adjustments (if any) to be made to the Initial Consideration
in accordance with clause 3.

1.3.
The provisions of this Part C of Schedule 4 and the line items comprising the
Completion Accounts shall be interpreted so as to avoid double counting (whether
positive or negative) of any items to be included in the Actual Net Cash.

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
49
 

--------------------------------------------------------------------------------

Part D: Preparation of Management Accounts
1. ACCOUNTING POLICIES
a. PRESENTATION OF MANAGEMENT ACCOUNTS
   CRITICAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the Company's accounting policies, management make
judgments, estimates and assumptions about the carrying amounts of assets and
liabilities that are not readily apparent from other sources. The estimates and
associated assumptions are based on historical experience and other factors that
are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis.
Revisions to accounting estimates are recognised in the period of the revision
and future periods if the revision affects both current and future periods.
b. OVERALL CONSIDERATIONS
The principal accounting policies adopted in the preparation of the management
accounts are set out below.
i. BASIS OF PREPARATION OF MANAGEMENT ACCOUNTS

These management accounts have been prepared in accordance with EU endorsed
International Financial Reporting Standards (IFRS) and interpretations issued by
the IFRS Interpretations Committee (IFRS IC) and the Companies Act 2006
applicable to companies reporting under IFRS. The management accounts have been
prepared under the historical cost convention.
ii.
GOING CONCERN

Management prepare management accounts on a going concern basis unless they
intend to liquidate the business or to cease trading, or have no realistic
alternative but to do so. In deciding whether the going concern basis is
appropriate, the directors examine existing budgets and forecasts, assess
borrowing requirements, and review other information as needed.
iii. NEW AND AMENDED STANDARDS ADOPTED BY THE COMPANY

In any period, new or amended standards and interpretations are considered for
adoption. Other standards, amendments and interpretations which are effective
for the period are considered where they material to the Company.

CONFIDENTIAL
50
 

--------------------------------------------------------------------------------

c. RECEIVABLES

Receivables are recognised initially at fair value less provision for
impairment. The Company provides an allowance for uncollectible accounts based
on prior experience and management’s assessment of the collectability of
existing specific accounts.
 
d.
CASH AND CASH EQUIVALENTS

Cash and cash equivalents comprises cash on hand and demand deposits, and other
short‑term and highly liquid investments with original maturities of three
months or less that are readily convertible to a known amount of cash and are
subject to an insignificant risk of changes in value.
e. EQUITY AND RESERVES

Ordinary and preferred shares are classified as equity. Issued capital
represents the nominal value of shares that have been issued. Retained earnings
includes all current period retained profits and accumulated losses.

f.
TRADE PAYABLES

Trade payables are obligations to pay for goods or services that have been
acquired in the ordinary course of business from suppliers. Trade and other
payables are stated at cost, which approximates fair value due to the short term
nature of these liabilities. Trade payables are classified as current
liabilities if payment is due within one period or less. If not, they are
presented as non-current liabilities.

g.
REVENUE RECOGNITION

Revenue is measured at the fair value of the consideration received or
receivable and is stated net of value added taxes. Revenue is recognised when it
is probable that future economic benefits will flow to the Company and those
benefits can be measured reliably. Revenue on the sale of an asset (e.g. the
outright sale or assignment of a licence) is only recognised when, inter alia,
the significant risks and rewards of ownership have been transferred to the
buyer and the Company does not retain either control of the goods, or continuing
involvement, to the degree associated with ownership.
Where, as part of a licence agreement, services are performed by an
indeterminate number of acts over a specified period of time, revenue for such
services is recognised on a straight-line basis over the specified period unless
there is evidence that some other method represents better the stage of
completion.
h.    SHARE BASED PAYMENTS

CONFIDENTIAL
51
 

--------------------------------------------------------------------------------

A share option compensation charge is not recognised in the monthly management
accounts.

i.
TAXATION AND DEFERRED TAX

A tax credit or charge is not reflected in the monthly management accounts.
Deferred tax is not reflected in the monthly management accounts.
j.
FINANCIAL INSTRUMENTS

i.
FINANCIAL ASSETS

All financial assets relate to trade and other receivables, which are stated at
their recoverable amount, which approximates the fair value due to the short
term nature of these assets.
ii. RISK MANAGEMENT POLICY

The Company undertakes transactions denominated in foreign currencies and as
such is exposed to currency risk due to fluctuations in foreign exchange rates.
The Company does not use derivative instruments to reduce exposure to foreign
exchange risk.
iii. FINANCIAL LIABILITIES

Trade and other payables are stated at cost. This approximates fair value due to
the short term nature of these liabilities.
k.
FOREIGN CURRENCY TRANSLATION

Foreign currency transactions are translated at the rates of exchange in effect
at the dates of the transaction. Resulting foreign currency denominated monetary
assets and liabilities are translated at the rates of exchange in effect at the
balance sheet date. Gains and losses on foreign exchange are recognised in the
income statement.

CONFIDENTIAL
52
 

--------------------------------------------------------------------------------

SCHEDULE 5
Contingent Consideration
Part A: Contingent Consideration
1.
Definitions

In this Schedule 5, and where applicable, the remainder of this Agreement, the
following definitions shall apply:
“Accepted Fcab Target” has the meaning given to it in the License Agreement,
with respect to events and circumstances before Completion and has the meaning
given to it in the Gamma IP License with respect to events and circumstances
after Completion;
“Commercialisation” has the meaning given to it in the License Agreement;
“Commercially Reasonable Efforts” has the meaning given to it in the License
Agreement;
“Conforming mAb2” means [***];
“Contingent Consideration” means any of the Milestone Payments;
“Default Notice” has the meaning given to it in paragraph 2.2 of this Part A of
Schedule 5;
“Denali Fcab” has the meaning given to it in the License Agreement;
“EU Regulatory Milestone” means [***];
“European Union” or “E.U.” has the meaning given to it in the License Agreement
and shall be deemed to include [***];
“Fcab Delivery” means, with respect to an Accepted Fcab Target, that an Fcab
that specifically binds to such Accepted Fcab Target has achieved “Fcab
Delivery” (as defined therein) under Section 4.3 or Section 9.11.1 of the
License Agreement or Section 4.1.2 of the Gamma Services Agreement during the
applicable Fcab Disclosure Period (as defined therein);

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
53
 

--------------------------------------------------------------------------------

“First Commercial Sale” has the meaning given to it in the License Agreement,
except that all references to Licensed Products in such definition will be read
as references to mAb2 Products;
“Fcab” has the meaning given to it in the License Agreement;
“Fcab Disclosure Period” has the meaning given to it in Section 1.3.3 of that
certain letter agreement between the Company, F-Star, F-Star GmbH and Buyer
dated and entered into on or about May ___, 2018;
“GMP” has the meaning given to it in the License Agreement;
“Initial Milestone” has the meaning given to it in the table in Part B of this
Schedule 5;
“Initial Payment True Up Event” means that [***];
“Joint Fcab” has the meaning given to it in the License Agreement;
“Licensor Fcab” has the meaning given to it in the License Agreement;
“mAb2 Product” means [***];
“Major EU Market” means [***].
“Milestone Event” means the relevant event as set out in column 1 of Part B of
this Schedule 5, which shall trigger the relevant Milestone Payment. In
addition:
a)
where [***], it shall be considered a “Milestone Event” in respect of which the
Buyer will pay to the Sellers a one-time payment (which shall constitute a
“Milestone Payment”) of [***];

b)
[intentionally left blank];

c)
[intentionally left blank]; and

d)
[***];

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
54
 

--------------------------------------------------------------------------------

“Milestone Payment” means, with respect to a Milestone Event:
a)
if [***], a payment equal to [***] of the “Maximum Milestone Payment” amount set
out column 2 of Part B of this Schedule 5 in the row corresponding to the
applicable Milestone Event; and

b)
if [***], a payment equal to [***] of the “Maximum Milestone Payment” amount set
out column 2 of Part B of this Schedule 5 in the row corresponding to the
applicable Milestone Event;

In no event will more than one Milestone Payment be made for a given Milestone
Event, regardless of how many mAb2 Products achieve such Milestone Event, except
that [***], then a second Milestone Payment shall become due with respect to
such Milestone Event, in an amount equal to [***] of the “Maximum Milestone
Payment” amount set out column 2 of Part B of this Schedule 5 in the row
corresponding to the applicable Milestone Event. For clarity, under no
circumstances will the total Milestone Payments that the Buyer becomes obligated
to make in respect to a given Milestone Event exceed the “Maximum Milestone
Payment” amount set out column 2 of Part B of this Schedule 5 in the row
corresponding to the applicable Milestone Event;
“Net Sales” means, with respect to a mAb2 Product for any period, the total
amount billed or invoices on sales of such mAb2 Product during such period by
the Buyer, its Affiliates or sublicensees, calculated in accordance with the
definition of “Net Sales” used in the License Agreement, and reading all
references to Licensed Products in such definition as references to mAb2
Products;
“Non-conforming mAb2” means a mAb2 Product that is not a Conforming mAb2;
“Payment Date” means the date which is 90 calendar days after any date on which
a Milestone Payment is triggered;
“Regulatory Approval” has the meaning given to it in the License Agreement;
“Relevant Period” means the period from Completion until [***];
“Remaining Amount” means the aggregate Contingent Consideration payable pursuant
to [***] minus the aggregate Contingent Consideration actually paid by the Buyer
pursuant to [***] prior to the date of delivery of a Default Notice;
*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
55
 

--------------------------------------------------------------------------------

“Risk-Adjusted Remaining Amount” means [***];
“Total Contingent Consideration” means the aggregate of the Milestone Payments;
and
“US Regulatory Milestone” means [***].
2.
Conduct of business during Relevant Period

Commercially Reasonable Efforts
2.1.
The Buyer shall during the Relevant Period use Commercially Reasonable Efforts
to achieve both of the EU Regulatory Milestone and the US Regulatory Milestone. 
The Sellers acknowledge and agree that, in addition to the foregoing:

(a)
the Buyer shall be deemed to have satisfied its obligations under this paragraph
2.1 of Schedule 5 so long as the Buyer is using Commercially Reasonable Efforts
to advance [***] toward achievement of the [***];

(b)
the Buyer shall have the right to satisfy its diligence obligations under this
paragraph 2.1 of Schedule 5 through its Affiliates or Sublicensees; and

(c)
nothing in this paragraph 2.1 of Schedule 5 is intended, or shall be construed,
to require the Buyer to Develop:

(i)
[***]; or

(ii)
[***] 

2.2.
If at any time the Sellers have a reasonable basis to believe that the Buyer is
in material breach of its obligations under paragraph 2.1 of Schedule 5 and such
material breach has continued for a period of at least [***] (a “Continuing
Material Breach”), then the Sellers shall cause the Sellers’ Representative to
deliver written notice (the “Default Notice”) of such Continuing Material Breach
to the Buyer and, if the Buyer fails to remedy such Continuing Material Breach
within 60 days of receipt of the Default Notice, then the provisions of
paragraph 2.3 shall apply.

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
56
 

--------------------------------------------------------------------------------

2.3.
If the Buyer is in Continuing Material Breach of its obligations under paragraph
2.1 and following receipt of a Default Notice fails to remedy such Continuing
Material Breach within the time period set out in paragraph 2.2, then the
Sellers’ Representative may, by written notice to the Buyer, elect to initiate
an ADR proceeding pursuant to the procedures set forth in clause 23.3, and the
arbitrators for such ADR proceeding shall be instructed and required to conduct
a proceeding for the sole purposes of [***]. In the event [***] the Buyer is in
Continuing Material Breach of its obligations under paragraph 2.1, the Buyer
shall pay to the Sellers [***] the Risk-Adjusted Remaining Amount.

2.4.
Any amount to be paid by the Buyer pursuant to paragraph 2.3:

(a)
to the Cash Sellers, shall be paid by transfer of the relevant funds for same
day value to the Payments Administrator,

(b)
to the Loan Note Sellers, shall be paid by the issue by the Buyer of Contingent
Consideration Loan Notes to each of the Loan Note Sellers equal, in principal
amount, to the relevant amount due to each of them pursuant to paragraph 2.3,

in each case shall be made within 30 Business Days of the expiry of the time
period set out in paragraph 2.2 without set off, deduction or withholding
(except as required by law or by this Agreement).
2.5.
The Sellers agree between themselves that any payments to the Payments
Administrator pursuant to paragraph 2.4 shall be apportioned, and the principal
amount of any Contingent Consideration Loan Notes issued pursuant to paragraph
2.4 shall be calculated, by reference to the Sellers’ respective Proportion of
Initial Consideration. The Buyer shall not be responsible for how any such
payment to the Payments Administrator is allocated or applied by the Payments
Administrator.

2.6.
A payment or issue of Contingent Consideration Loan Notes by the Buyer pursuant
to paragraph 2.3 shall not discharge the Buyer of its obligation to pay any
further Contingent Consideration (if any) above the amounts paid to the Sellers
in accordance with paragraph 2.3 upon achievement of the relevant Milestone
Events.

2.7.
The parties acknowledge that:

(a)
any provision in this Agreement that imposes a detriment on a party in breach,
in particular as set out in paragraph 2.3 of this Part A of Schedule 5,
represents a genuine pre-estimate of the loss expected to be suffered by the
party not in breach, and:

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
57
 

--------------------------------------------------------------------------------

(i)
protects the legitimate interests of the other parties in the enforcement of the
obligation breached; and

(ii)
is not out of all proportion to those legitimate interests; and

(b)
they are of comparable bargaining power and each of them has been properly
advised in relation to this Agreement.

Record Keeping and Reporting
2.8.
The Buyer agrees that during the period whilst further Contingent Consideration
is payable in accordance with this Schedule 5 it shall, and shall procure that
each other Buyer’s Group Undertaking shall:

(a)
prepare and maintain reasonably complete and accurate records regarding any
Commercialisation or Development efforts which relate to any mAb2 Product and
all other data necessary for the calculation of the Contingent Consideration;

(b)
once per calendar year, on 31 January, and subject to reasonable procedures and
agreements to preserve confidentiality, provide the Sellers’ Representative with
a written report on material developments with respect to the Development and
Commercialisation of any mAb2 Product, together with such reasonable additional
information regarding any such activities or events as the Sellers’
Representative may reasonably request from time to time (subject to any
applicable third party confidentiality restrictions) which shall include copies
of relevant documents as requested by the Sellers’ Representative; and

(c)
once per calendar year during the Relevant Period, within 30 days of the
Sellers’ Representative’s written request, meet in person or by telephone with
the Sellers’ Representative. At such meetings, the Buyer shall cause senior
officers from the research, clinical development, and business operations of the
Buyer and/or the Buyer’s Group Undertakings to attend, to present and to answer
questions. Each of the Buyer and the Sellers’ Representative (on behalf of the
Sellers) shall bear its own costs and expenses regarding such meetings.

2.9.
Upon receipt of a request from the Sellers’ Representative, the Buyer shall, and
shall ensure each of Buyer’s Group Undertakings shall, permit an independent
auditor designated by the Sellers’ Representative to inspect and audit the
records and books of account maintained by it pursuant to paragraph 2.8 in order
to confirm the accuracy and completeness of such records and books of account
and the calculation of the Contingent Consideration. Any such audit shall (i) be
for a reasonable duration during office hours on a Business Day; (ii) be upon
notice of at least 30 days; and (iii) not be requested more than once during
each

CONFIDENTIAL
58
 

--------------------------------------------------------------------------------

financial year of the period during which any Contingent Consideration remains
payable. The Sellers’ Representative (on behalf of the Sellers) shall pay the
costs of each audit unless the audit reveals a variance of more than [***]
between the amounts paid and the amounts due, in which case the Buyer shall bear
the cost of the audit, provided, however, that in the event the audit pertains
to achievement of a Milestone Event relating to the Buyer’s Net Sales, the
Sellers’ Representative (on behalf of the Sellers) shall pay the costs of each
audit unless the audit reveals a variance of more than [***] between the Net
Sales reported by Buyer and the Net Sales determined by the audit. If the audit
reveals an underpayment by the Buyer, the Buyer shall transfer the amount by
which it had underpaid by transfer of funds for same day value to the Payments
Administrator for further distribution to the Sellers within 10 Business Days
after the date on which such audit is completed.

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
59
 

--------------------------------------------------------------------------------

Part B: Milestone Payment Amounts
Column 1: Milestone Event
Column 2: Maximum Milestone Payment (US$)
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
TOTAL =
[***]

* The maximum Milestone Payment for this Milestone Event shall be increased by
[***].

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
60
 

--------------------------------------------------------------------------------

SCHEDULE 6
[***]
Part A: [***]
1.
CAPACITY AND AUTHORITY

1.1.
The Seller has the right, power and authority to execute, deliver and perform
its obligations under this Agreement and any other Transactional Document to be
executed by the Seller and, where the Seller is not an individual, all such
obligations of the Seller have been duly and validly approved and authorized by
all necessary action on the part of such Seller, and no other action on the part
of such Seller is required in connection therewith.

1.2.
If such Seller is not an individual, it has been duly incorporated and is
validly existing and in good standing under the laws of the jurisdiction in
which it is incorporated or constituted (to the extent that such concepts are
recognised in such jurisdiction).

1.3.
The Seller’s obligations under this Agreement and any other Transactional
Document to be executed by the Seller are, or when the relevant document is
executed will be, enforceable in accordance with their terms, subject to the
effects of bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other similar laws relating to or affecting creditors’ rights
generally and general equitable principles

1.4.
The execution and delivery of, and the performance by the Seller of its
obligations under, this Agreement and any of the Transactional Documents will
not:

(a)
if relevant, result in a breach of any provision of its articles of association
or by-laws;

(b)
result in a breach of, or constitute a default under, any instrument to which
the Seller is a party or by which the Seller is bound where such breach may
prejudice the transactions contemplated by this Agreement or any of the
Transaction Documents; or

(c)
result in a breach of any order, judgment or decree of any court or Authority to
which the Seller is a party or by which the Seller is bound or submits where
such breach may prejudice the transactions contemplated by this Agreement or any
of the Transaction Documents.

CONFIDENTIAL
61
 

--------------------------------------------------------------------------------

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.
2.
SHARES

2.1.
The Seller’s Relevant Shares constitute the whole of the Seller’s interest in
the allotted and issued share capital of the Company and the Seller does not
exercise voting power over any other outstanding shares or other equity
interests of the Company.

2.2.
The Seller is entitled to sell and transfer or procure the transfer of the full
legal and beneficial ownership of its Relevant Shares to the Buyer on the terms
set out in this Agreement.

2.3.
The Shares registered in the name of the Seller and set out opposite his name at
columns B and C (as applicable) of Schedule 1 have been properly allotted and
issued and are fully paid and such Shares will be sold free of all Encumbrances
and there is no agreement, arrangement or obligation to give or create any such
Encumbrance. No person has claimed to be entitled to an Encumbrance in relation
to any such Shares.

CONFIDENTIAL
62
 

--------------------------------------------------------------------------------

Part B: [***]
1.
SHARES

1.1.
At Completion, the Shares are registered in the name of the Sellers and set out
opposite their names at columns B and C (as applicable) of Schedule 1 and
constitute the entire issued share capital of the Company, have been properly
allotted and issued and are fully paid or credited as fully paid.

1.2.
Other than this Agreement, the Transaction Documents, the Shareholders’
Agreement or as referred to or contemplated by this Agreement, there is no
agreement, arrangement or obligation requiring the creation, allotment, issue,
transfer, redemption or repayment of, or the grant to a person by the Company of
the right (conditional or not) to require the allotment, issue, transfer,
redemption or repayment of, a share in the capital of the Company (including an
option or right of pre emption or conversion).

1.3.
So far as the Warrantors are aware, no person has claimed to be entitled to an
Encumbrance in relation to any Shares.

1.4.
Save for this Agreement, the Transaction Documents, the Company’s articles of
association and the Shareholders’ Agreement, there are no contracts relating to
voting, purchase, sale or transfer of any Shares (i) between or among the
Company and any Shareholder, and (ii) so far as the Warrantors are aware,
between or among any of the Shareholders.

2.
THE GROUP

2.1.
The Company does not have, and has not at any time had, any subsidiary
undertakings.

2.2.
Other than as contemplated by this Agreement, the Company has no interest in,
and has not agreed to acquire an interest in or merge or consolidate with, a
corporate body or any other person.

2.3.
The information contained in Schedule 1 (The Sellers) and Schedule 2
(Information about the Company) is true and accurate.

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
63
 

--------------------------------------------------------------------------------

SCHEDULE 7
[***]
1.
ORGANIZATION

1.1
The Company is a company duly incorporated and validly existing under the laws
of England and Wales and has the right, power and authority to execute, deliver
and perform its obligations under this Agreement and any other Transactional
Document to be executed by it.

1.2
The Company’s obligations under this Agreement and any other Transactional
Documents to be executed by the Company are, or when the relevant document is
executed will be, enforceable in accordance with their terms, subject to the
effects of bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other similar laws relating to or affecting creditors’ rights
generally and general equitable principles.

2.
ACCOUNTS

2.1
General

2.1.1
The Accounts have been prepared and audited on a proper and consistent basis in
accordance with the law and applicable standards, principles and practices
generally accepted in the United Kingdom.

2.1.2
The Accounts show a true and fair view of the state of affairs of the Company as
at the Last Accounting Date and of the profit or loss of the Company for the
financial year ended on the Last Accounting Date.

2.1.3
Save as disclosed in the Accounts, the Accounts have been prepared using the
same accounting policies as those adopted and applied in preparing the accounts
for the previous two years.

2.1.4
The Company does not have any liabilities of any nature other than (i) those set
forth or adequately provided for in the Accounts, (ii) those incurred in the
conduct of the Company’s business since the Last Accounting Date in the ordinary
course, and which, individually or in the aggregate, are not material in nature
or amount and do not result from any breach by the Company of any contract,
warranty, infringement, tort or violation of law to which it is subject, and
(iii) those incurred by the Company in connection with the execution of this
Agreement. Except for liabilities reflected in the Accounts, the Company has no
off balance sheet liability of any nature to, or any material financial interest
in, any third party or entities, the purpose or effect of which is to defer,
postpone, reduce or otherwise avoid or adjust the recording of expenses incurred
by the Company. Without limiting the generality of the foregoing, the Company
has never guaranteed any debt or other obligation of any other person.

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
64
 

--------------------------------------------------------------------------------

2.2
Provision for Tax

The Accounts include provision or reserve (as appropriate) in accordance with
the relevant accounting standards for Tax liable to be assessed on the Company
or for which the Company is accountable in respect of profits earned, accrued or
received on or before the Last Accounting Date, and in respect of any event
occurring on or before the Last Accounting Date.
2.3
Accounting records

The Company’s accounting records are up-to-date in all material respects, are in
its possession or under its control and are properly completed in accordance
with the law and applicable standards, principles and practices generally
accepted in the United Kingdom.
3.
CHANGES SINCE THE LAST ACCOUNTING DATE

3.1
Since the Last Accounting Date:

3.1.1
the Company’s business has in all material respects been operated in the usual
way so as to maintain it as a going concern;

3.1.2
there has been no material adverse change in the financial or trading position
of the Company or the properties, assets (including intangible assets),
liabilities, business, prospects, capitalization, employees, operations or
results of operations of the Company or any change that would reasonably be
expected to materially impede or delay the Company’s ability to consummate the
transactions contemplated by this Agreement, other than any event, circumstance
or change resulting from changes in stock markets, interest rates, exchange
rates, commodity prices or other general economic conditions or changes in
conditions affecting the industry generally in which the Company operates;

3.1.3
the Company has not made or entered into any contract or letter of intent with
respect to, or otherwise effected, any acquisition, sale, license, disposition
or transfer of any asset that is material to the business of the Company,
including without limitation, Intellectual Property other than IP Licenses Out;

3.1.4
there has not occurred any change in accounting methods or practices (including
any change in depreciation or amortization policies or rates or revenue
recognition policies or establishment of reserves) by the Company or any
revaluation by the Company of any of its assets;

3.1.5
there has not occurred any declaration, setting aside, or payment of a dividend
or other distribution with respect to any securities of the Company, or any
redemption, purchase or other acquisition by the Company of any of its
securities, or any change in any rights, preferences, privileges or restrictions
of any of its outstanding securities;

CONFIDENTIAL
65
 

--------------------------------------------------------------------------------

3.1.6
the Company has not entered into, amended, renewed or terminated any Material
Contract (as hereinafter defined), and there has not occurred any material
default or breach under any Material Contract to which the Company is a party or
by which it is, or any of its assets and properties are, bound;

3.1.7
the Company has not incurred, created or assumed any Encumbrance on any of its
assets or properties, any material indebtedness, or any liability as guarantor
or surety with respect to the obligations of any other person; and

3.1.8
the Company has not paid or discharged any Encumbrance or liability which was
not shown on the Accounts or incurred in the ordinary course of business
consistent with past practice since the Last Accounting Date.

4.
TAX

4.1
The Company has, within the last three years, where legally obliged to do so:

4.1.1
duly and punctually paid all Tax which it has become liable to pay, whether or
not shown or required to be shown on any Tax return;

4.1.2
duly deducted, withheld or collected for payment (as appropriate) all Tax due to
have been deducted, withheld or collected for payment and has accounted for or
paid all such Tax to the relevant Tax Authority (to the extent due); and

4.1.3
not been liable to pay any material interest, penalty or surcharge in respect of
any unpaid Tax.

4.2
All returns, computations, information, accounts and notices which are or have
been required by law to be made or given by the Company within the last three
years for any Tax purposes have been made or given in the required form and have
been properly submitted by the Company and are complete and accurate in all
material respects.

4.3
The Company has, in the last three years, in all material respects, complied at
all times with all statutory requirements, regulations, notices, orders,
directions and conditions relating to all relevant Taxes, including the terms of
any agreement made with HMRC or any other relevant Tax Authority.

4.4
The Company is not, nor has it at any time within the last three years, been
involved in any dispute with or non-routine investigation, audit or discovery by
any Tax Authority and, so far as the Warrantors are aware, no such dispute,
investigation, audit or discovery is planned.

4.5
There are no liens or encumbrances against any of the Company’s assets, arising
in connection with a failure to pay any Tax.

4.6
In the last three years, each related party transaction involving the Company is
and has been at arm's-length in all material respects and determined in
compliance in all material respects with applicable transfer pricing rules and
regulations.

CONFIDENTIAL
66
 

--------------------------------------------------------------------------------

4.7
The Company does not have any outstanding waivers or extension of the statute of
limitations for assessment of any Tax.

4.8
The Company is not a party to, or bound by, any Tax indemnity agreement, Tax
sharing agreement or Tax allocation agreement with respect to Taxes (other than
any agreement entered into in the ordinary course of business and not primarily
related to Taxes) and other than this Agreement, the Spin-Out License, and the
License Agreement and any other agreement contemplated by any such agreements.
The Company is not liable for Taxes of any other Person (i) under any applicable
Law, (ii) as a transferee of any assets or successor to any liabilities, or
(iii) by Contract, indemnity or otherwise, including by reason of the
transactions contemplated by the Gamma IP License.

4.9
In the last three years, no written claim has been made by any Tax Authority in
a jurisdiction where the Company does not file Tax Returns that the Company is
or may be subject to Taxation by that jurisdiction.

4.10
The Company will not, after the Completion Date, be liable under any applicable
Law, by Contract, indemnity or otherwise as a transferee of any assets or
successor to any liabilities, for any Taxes of F-star, F-star GmbH, or any of
their Affiliates as a result of (i) the Company’s entry into, and transactions
contemplated by, the Gamma IP License, the License Agreement and the Services
Agreement and/or (ii) the transactions contemplated by the Option Agreement and
this Agreement other than VAT as provided for in any agreement.

5.
ASSETS

5.1
Title and condition

5.1.1
Each asset included in the Accounts or acquired by the Company since the Last
Accounting Date is:

(a)
legally and beneficially owned solely by the Company;

(b)
where capable of possession, in the possession or under the control of the
Company.

5.1.2
Company owns or has the right to use each asset used in and necessary for the
effective operation of its business.

6.
INTELLECTUAL PROPERTY

The Company owns, or has rights to use, all Intellectual Property materially
necessary for the Company to operate its business.
6.1
Registered Owned IP

6.1.1
The Disclosure Letter sets out details of all material registered Intellectual
Property owned by the Company (“Registered Owned IP”). The Company solely owns
the Registered Owned IP.

CONFIDENTIAL
67
 

--------------------------------------------------------------------------------

6.1.2
To the best of the knowledge, information and belief of the Warrantors, (i)
there are no issued patents or registered trademarks within the Registered Owned
IP that are invalid or unenforceable and (ii) there are no patent applications
included within the Registered Owned IP that have not been duly filed and
diligently prosecuted.

6.1.3
The Company has received an assignment of rights from each inventor listed in
the patents and patent applications included in the Disclosure Letter save in
the case of those inventors which are employees of the Company and whose
inventions vest in the Company by virtue of their employment relationship. The
Company is the sole legal and beneficial owner of each of the patents and patent
applications.

6.1.4
All issuance, renewal and maintenance fees due up to and including the date of
this Agreement in respect of each of the Registered Owned IP have been paid in
full and on time.

6.2
No infringement by Company of third party Intellectual Property

6.2.1
To the best of the knowledge, information and belief of the Warrantors, the
activities of the Company, and the practice of the inventions claimed under the
Registered Owned IP, do not nor have they in the year prior to the date of this
Agreement infringed, misappropriated, misused, violated or otherwise made use
without authorisation of any third party Intellectual Property nor has any
person threatened to the Company in writing to issue such a notice.

6.2.2
To the best of the knowledge, information and belief of the Warrantors, the
Company has not issued any opposition, invalidation, revocation or cancellation
proceeding or any other proceeding or counterclaim (including any litigation,
arbitration or proceeding pursuant to any other dispute resolution mechanism)
concerning the validity, enforceability or title to any Intellectual Property of
any third party.

6.3
IP Licenses In and IP Licenses Out

6.3.1
Copies of all material licenses of Intellectual Property granted by the Company
(“IP Licenses Out”) and granted to the Company (“IP Licenses In”) are included
in the Disclosure Bundle.

6.3.2
To the best of the knowledge, information and belief of the Warrantors, no IP
License In or IP License Out is currently being, or has at any time been,
breached in a material way by the Company or to the best of the Warrantors’
knowledge, information and belief, by any other party thereto. So far as the
Warrantors are aware, the rights granted under the IP Licenses In and IP
Licenses Out will not be adversely affected by the transactions contemplated by
this Agreement.

6.3.3
To the best of the knowledge, information and belief of the Warrantors, all
fees, royalties or other amounts due to be paid by or to the Company in respect
of any IP License In or IP License Out have been paid in a timely manner and no
such payments have been outstanding for more than 60 days.

CONFIDENTIAL
68
 

--------------------------------------------------------------------------------

6.4
Company Confidential Information

6.4.1
To the best of the knowledge, information and belief of the Warrantors, all
Company Confidential Information held by the Company is accurately and properly
documented to enable the Buyer to acquire and retain its full benefit and is
subject to appropriate storage and security measures to preserve the
confidentiality and secrecy of such Company Confidential Information.

6.4.2
To the best of the knowledge, information and belief of the Warrantors, the
Company has not disclosed any Company Confidential Information to any person
other than (i) its employees and advisors who are bound by obligations of
confidence (howsoever arising); (ii) in circumstances where such disclosures
have been made in the ordinary course of business; and (iii) pursuant to the IP
Licenses Out and the IP Licenses In.

7.
INSURANCE

7.1
Policies

The Disclosure Letter sets out a list of insurance policies maintained by or on
behalf of the Company (together the “Policies”);
7.2
Status of the Policies

Each of the Policies is valid and enforceable and the Warrantors are not aware
of any circumstances that would render any of them void or voidable.
7.3
Premiums

All premiums which are due under the Policies have been paid.
8.
MATERIAL CONTRACTS

8.1
Validity of Material Contract

8.1.1
Save for the Transaction Documents. the Company is not a party to or bound by
any of the following contracts (each a “Material Contract”):

(a)
any contract limiting the freedom of the Company to engage or participate, or
compete with any other person, in any line of business, market or geographic
area, or to make use of any Intellectual Property, or any contract granting
exclusive rights, rights of refusal, rights of first negotiation or similar
rights and/or terms to any person, or any contract otherwise limiting the right
of the Company to sell, distribute or manufacture any products or services or to
purchase or otherwise obtain any products or services;

(b)
any licenses, sublicenses and other contracts pursuant to which any person is
granted any rights to Intellectual Property of the Company or pursuant to which
the Company has agreed to any restriction on the right of the Company

CONFIDENTIAL
69
 

--------------------------------------------------------------------------------

to use or enforce any Intellectual Property owned by the Company or pursuant to
which the Company agrees to encumber, transfer or sell rights in or with respect
to any Intellectual Property owned by the Company; or
(c)
any other contract or obligation that individually had or has a value or payment
obligation in excess of US$50,000 over the life of the contract or is otherwise
material to the Company or its businesses, operations, financial condition,
properties or assets.

8.1.2
Each of the Material Contracts is in full force and effect, subject only to the
effect, if any, of applicable bankruptcy and other similar laws affecting the
rights of creditors generally and rules of law governing specific performance,
injunctive relief and other equitable remedies.

8.1.3
No party to a Material Contract has given notice of its intention to terminate
to the Company, or has sought to repudiate or disclaim, the Material Contract.

8.1.4
Neither the Company nor, so far as the Warrantors are aware, any party with whom
the Company has entered into a Material Contract is in material breach of the
Material Contract.

8.1.5
So far as the Warrantors are aware, no circumstances exist which would give rise
to any breach of any Material Contract or to any such Material Contract being
terminated or varied without the Company’s consent (other than termination
without cause upon notice in accordance with the terms of the agreement).

9.
EFFECT OF SALE

Neither the execution nor the performance of this Agreement or any document to
be executed at or before the Completion Date will result in the Company losing
the benefit of any material asset, grant, subsidy, right or privilege which it
enjoys at the date of this Agreement.
10.
LIABILITIES

10.1
Indebtedness

The Company does not have outstanding and has not agreed to create or incur loan
capital, borrowings, indebtedness in the nature of borrowings other than the
trade debt incurred in the ordinary and usual course of trading.
10.2
Guarantees and indemnities

The Company is not a party to and is not liable under a guarantee, indemnity or
other agreement to secure or incur a financial or other obligation with respect
to another person’s obligation.
10.3
Grants

CONFIDENTIAL
70
 

--------------------------------------------------------------------------------

10.3.1
The Company is not liable to repay an investment or other grant or subsidy made
to it by a body (including the Department for Business, Innovation and Skills or
its predecessor).

10.3.2
No fact or circumstance (including the execution and performance of this
Agreement) exists which might entitle a body to require repayment of, or refuse
an application by the Company for, the whole or part of a grant or subsidy.

11.
RESTRICTIONS ON BUSINESS ACTIVITIES

Other than the Transaction Documents, there is no contract, judgment,
injunction, order or decree binding upon the Company as of the date of this
Agreement which has or would reasonably be expected to have, whether before or
after Completion, the effect of prohibiting, restricting or impairing any
current or presently proposed business practice of the Company, any acquisition
of property by the Company or the conduct or operation of the Company’s business
or limiting the freedom of the Company to engage in any line of business, to
sell, license or otherwise distribute services or products in any market or
geographic area, or to compete with any person.
12.
SERVICE PROVIDERS

12.1
The Company has never employed or engaged any employees, consultants, advisory
board members, or independent contractors. The Company has never maintained or
offered any:

12.1.1
employee benefit plans;

12.1.2
loan to any independent contractor or consultant;

12.1.3
stock option, stock purchase, phantom stock, stock appreciation right,
supplemental retirement, severance, sabbatical, medical, dental, vision care,
disability, employee relocation, cafeteria benefit, dependent care, life
insurance or accident insurance plans, programs or arrangements;

12.1.4
bonus, pension, profit sharing, savings, severance, retirement, deferred
compensation or incentive plans, programs or arrangements;

12.1.5
other fringe or employee benefit plans, programs or arrangements; or

12.1.6
employment or executive compensation or severance agreements, written or
otherwise.

12.2
None of the execution and delivery of this Agreement, the Completion or any
other transaction contemplated hereby or any termination of employment or
service or any other event in connection therewith or subsequent thereto will,
individually or together or with the occurrence of some other event:

12.2.1
result in any payment (including severance, unemployment compensation, golden
parachute, bonus or otherwise) becoming due to any person;

CONFIDENTIAL
71
 

--------------------------------------------------------------------------------

12.2.2
increase or otherwise enhance any benefits otherwise payable by the Company;

12.2.3
result in the acceleration of the time of payment or vesting of any such
benefits;

12.2.4
obligate the payment of compensation to any person; or

12.2.5
result in the forgiveness in whole or in part of any outstanding loans made by
the Company to any person.

13.
INTERESTED PARTY TRANSACTIONS

None of the officers and directors of the Company and, as far as the Warrantors
are aware, none of the employees of the Company or Shareholders, nor, so far as
the Warrantors are aware, any immediate family member of an officer, director,
employee or Shareholder, has any direct or indirect ownership, participation, or
other interest in, or is an officer, director, employee of or consultant or
contractor for any firm, partnership, entity or corporation that competes with,
or does business with, or has any contractual arrangement with, the Company
(except with respect to (i) F-star or F-star GmbH or (ii) any interest in less
than five per cent (5%) of the issued share capital of any Company whose shares
are publicly traded). None of said officers, directors or Shareholders or, so
far as the Warrantors are aware, any employees or member of their immediate
families of the foregoing, is a party to or otherwise directly interested in,
any contract to which the Company is a party or by which the Company or any of
its assets or properties may be bound or affected in a material manner. As far
as the Warrantors are aware, none of said officers, directors, employees or
Shareholders has any material interest in any property, real or personal,
tangible or intangible (including any Intellectual Property) that is directly
related to the business of the Company.
14.
COMPLIANCE WITH OPTION AGREEMENT

At all times since the Effective Date (as defined in the Option Agreement) the
Company has complied in all material respects with its covenants set forth in
the Option Agreement.
15.
INSOLVENCY, WINDING UP ETC.

15.1
Winding up

No order has been made, petition presented or resolution passed for the winding
up of the Company or for the appointment of a liquidator or provisional
liquidator to the Company.
15.2
Administration

No administrator has been appointed in relation to the Company. So far as the
Warrantors are aware, no notice has been given or filed with the court of an
intention to appoint an administrator. No petition or application has been
presented or order made for the appointment of an administrator in respect of
the Company.
15.3
Receivership

CONFIDENTIAL
72
 

--------------------------------------------------------------------------------

No receiver or administrative receiver has been appointed, nor any notice given
of the appointment of any such person, over the whole or part of the Company’s
business or assets.
15.4
Moratorium

No moratorium has been sought or has been granted under section 1A of the
Insolvency Act 1986 in respect of the Company.
15.5
Voluntary arrangements

No voluntary arrangement has been proposed under section 1 of the Insolvency Act
1986 in respect of the Company.
15.6
Scheme of arrangement

No compromise or arrangement has been proposed, agreed to or sanctioned under
Part 26 (Arrangements and Reconstructions) of the Act in respect of the Company,
nor has any application been made to, or filed with, the court for permission to
convene a meeting to vote on a proposal for any such compromise or arrangement.
15.7
Informal arrangements with creditors

The Company has not proposed or agreed to a composition, compromise, assignment
or arrangement with any of its creditors.
15.8
Inability to pay debts

The Company is not unable to pay its debts within the meaning of section 123 of
the Insolvency Act 1986. There are no unsatisfied written demands that have been
served on the Company pursuant to section 123(1)(a) of the Insolvency Act 1986.
There is no unsatisfied judgment or court order outstanding against the Company.
15.9
Payment of debts

The Company has not stopped payment of, nor is it unable to pay, its debts as
they fall due, nor has the Company commenced negotiations with one or more of
its creditors with a view to rescheduling or restructuring any of its
indebtedness.
15.10
Distress

No distress, execution, attachment, sequestration or other process has been
levied on an asset of the Company which remains undischarged.
15.11
Striking out

No action is being taken by the Registrar of Companies to strike the Company off
the register under section 1000 of the Act.
15.12
Analogous proceedings

CONFIDENTIAL
73
 

--------------------------------------------------------------------------------

The Company is not, in any jurisdiction, subject to or threatened by any other
procedures or steps which are analogous to those set out above.
16.
COMPETITION

So far as the Warrantors are aware, the Company has not failed to comply with or
infringed the competition laws or regulations of any jurisdiction or been
investigated for alleged non-compliance or infringement or given any undertaking
in connection therewith.
17.
LITIGATION AND COMPLIANCE WITH LAW

Nothing in this Warranty concerns any matters concerned with any Intellectual
Property.
For the purposes of this paragraph 12:
“Agent” means, with respect to an entity, any director, officer, employee or
other representative of such entity; any person for whose acts such entity may
be vicariously liable; and any other person that acts for or on behalf of, or
provides services for or on behalf of, such entity, in each case, whilst acting
in his capacity as such;
17.1
Litigation

17.1.1
Neither the Company nor, so far as the Warrantors are aware, a person for whose
acts or defaults the Company may be vicariously liable is involved, or has been
involved, in a civil, criminal, arbitration, administrative or other proceeding.
The Company has not received written notice that any civil, criminal,
arbitration, administrative or other proceeding is pending or threatened by or
against the Company or the assets or properties of the Company, or any of the
directors, officers or employees of the Company (in their capacities as such or
relating to their employment, services or relationship with the Company) or, so
far as the Warrantors are aware, a person for whose acts or defaults the Company
may be vicariously liable. So far as the Warrantors are aware, there is no
reasonable basis for any action, suit, proceeding, claim, mediation, arbitration
or investigation against the Company or the assets or properties of the Company,
or any of the directors, officers or employees of the Company (in their
capacities as such or relating to their employment, services or relationship
with the Company) or a person for whose acts or defaults the Company may be
vicariously liable.

17.1.2
There is no outstanding judgment, order, decree, arbitral award or decision of a
court, tribunal, arbitrator or governmental agency against the Company, any of
its assets or properties, or a person for whose acts or defaults the Company may
be vicariously liable.

17.1.3
So far as the Warrantors are aware, there is no reasonable basis for any Person
to asset a claim against the Company based upon the Company entering into this
Agreement or any of the Transaction Documents.

CONFIDENTIAL
74
 

--------------------------------------------------------------------------------

17.2
Compliance with law

17.2.1
The Company has conducted its business and dealt with its assets in all material
respects in accordance with applicable legal and administrative requirements.

17.2.2
The Company has obtained each governmental consent, license, permit, grant, or
other authorization of a governmental entity that is required for the operation
of the Company’s business or the holding of its assets or properties (all of the
foregoing consents, licenses, permits, grants, and other authorizations,
collectively, the “Company Authorizations”) and all of the Company
Authorizations are in full force and effect. The Company has not received any
notice or other communication from any governmental entity regarding (i) any
actual or possible violation of law or of any Company Authorization or any
failure to comply with any term or requirement of any Company Authorization or
(ii) any actual or possible revocation, withdrawal, suspension, cancellation,
termination or modification of any Company Authorization. None of the Company
Authorizations will be terminated or impaired, or will become terminable, in
whole or in part, as a result of the consummation of the transactions
contemplated by this Agreement.

17.3
Investigations

There is not and has not been any governmental or other investigation, enquiry
or disciplinary proceeding concerning the Company that the Company has been
notified of and, so far as the Warrantors are aware, none is pending or
threatened.
17.4
Making unlawful payments

Neither the Company nor, so far as the Warrantors are aware, any of its Agents
has paid, offered, promised, given or authorised the payment of money or
anything of value directly or indirectly to any person:
17.4.1
intending to induce a person to improperly perform a function or activity or to
reward a person for any such performance; or

17.4.2
while knowing or believing that the acceptance by that person would constitute
the improper performance of a function or activity.

17.5
Receiving unlawful payments

Neither the Company nor so far as the Warrantors are aware, have any of its
Agents has directly or indirectly requested, agreed to receive or accepted money
or anything of value:
17.5.1
as a reward for the improper performance of a function or activity by any
person;

17.5.2
in circumstances which amount to an improper performance of a function or
activity; or

17.5.3
intending that as a consequence of any such request, agreement to receive or
acceptance a function or activity will be performed improperly.

CONFIDENTIAL
75
 

--------------------------------------------------------------------------------

SCHEDULE 8
Limitations on Sellers’ Liability
1.
LIMITATION ON QUANTUM

1.1.
No Warrantor shall be liable in respect of [***] unless and until the amount
that would otherwise be recoverable from the Warrantors (in aggregate) in
respect of [***], when aggregated with any other amounts recoverable in respect
of [***] exceeds [***] (the “Threshold”), in which case the Warrantors shall be
liable [***].

1.2.
The total aggregate liability of the Warrantors in respect of [***] shall be
limited in accordance with clause 6.3.

1.3.
The liability in respect of each Seller in respect of [***] shall be limited to
a maximum amount equal to [***] of the aggregate of the Total Consideration paid
to such Seller, except for [***] with respect to [***] set forth in [***], which
shall be limited to a maximum amount of [***]. The liability in respect of each
Seller in respect of [***] shall be limited to a maximum amount equal to [***],
except in the case of [***], which shall be limited to a maximum amount of
[***].

1.4.
The liability of each Seller, in respect of [***] made against such Seller, and
the liability of each Warrantor for [***] made against such Warrantor, shall be
limited to a maximum amount equal to [***].

1.5.
Subject to paragraph 4 of this Schedule 8, the aggregate liability of any Seller
for all claims under this Agreement shall be limited to a maximum amount equal
to [***].

2.
TIME LIMITATIONS

2.1.
No Seller, in respect of [***], or Warrantor, in respect of [***], shall be
liable for such Claim (as the case may be) unless the Buyer has given the
Sellers’ Representative and each Warrantor notice of such Claim (as the case may
be), which notice shall state in reasonable detail the nature of the Claim, the
grounds on which it is based (including which Warranty has or Warranties have
been breached) and a good faith estimate of the amount claimed and must be
notified to the Sellers’ Representative or Warrantor (as the case may be):

(a)
on or before the date that is [***] after the Completion Date in respect of
[***];

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
76
 

--------------------------------------------------------------------------------

(b)
on or before [***] in respect of [***]; or

(c)
on or before [***] in respect of [***].

2.2.
No Seller shall be liable for [***] or Warrantor shall be liable for [***]
unless proceedings in respect of such Claim (as the case may be) are issued and
served on the Sellers’ Representative within a period of [***] starting on the
day of the Buyer’s notification of such Claim pursuant to Section 2.1 above and
provided that such Claim has not otherwise been satisfied, settled or withdrawn.

3.
RECOURSE FOR [***]

In the event that any Seller is liable to the Buyer in respect of [***]
following the earlier of (i) exhaustion of the money standing to the credit of
the Escrow Account and (ii) the Release Date, the Buyer’s [***] recourse for
such liability shall be [***].
4.
NO LIMITATION FOR FRAUD ETC.

Nothing in this Schedule 8 shall have the effect of limiting or restricting any
liability of any Seller or Warrantor in respect of a Claim arising as a result
of any fraud, wilful misconduct or wilful concealment by or on behalf of that
Seller or Warrantor.
5.
RECOVERY ONLY ONCE

The Buyer is not entitled to recover more than once in respect of any one matter
giving rise to a loss or liability under this Agreement.
6.
THIRD PARTY RECOVERY

6.1.
If the Sellers pay to a Buyer’s Group Undertaking an amount in respect of a
Claim and a Buyer’s Group Undertaking subsequently recovers from another person
an amount which is referable to the matter giving rise to the Claim:

(a)
if the amount paid by the Sellers in respect of the Claim is more than the Sum
Recovered, the Buyer shall promptly pay to the Sellers the Sum Recovered; and

(b)
if the amount paid by the Sellers in respect of the Claim is less than or equal
to the Sum Recovered, the Buyer shall promptly pay to the Sellers an amount
equal to the amount paid by the Sellers.

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
77
 

--------------------------------------------------------------------------------

For the purposes of paragraph 6.1 of this Schedule 8, “Sum Recovered” means an
amount equal to the total of the amount recovered from the other person plus any
interest in respect of the amount recovered from that person less all reasonable
costs incurred by a Buyer’s Group Undertaking in recovering the amount from the
person.
6.2.
If the Buyer or a Buyer’s Group Undertaking becomes aware that matters have
arisen which will or could reasonably be expected to give rise to a Claim, the
Buyer will (or will procure that the relevant Buyer’s Group Undertaking will)
where practicable (and provided such information is not subject to
confidentiality or is not privileged) disclose in writing to the Sellers’
Representative such information and documents relating to the Claim as the
Sellers’ Representative may reasonably request (at the sole cost of the Sellers)
and will consult with those Sellers to the extent practicable and have regard to
their reasonable representations in respect of the resolution of the Claim.

7.
ACCOUNTS

The Sellers shall have no liability in respect of any Claim if and to the extent
that any allowance, provision or reserve was made or otherwise reflected in the
Accounts or the Completion Accounts in respect of the matter or circumstances
giving rise to the Claim.
8.
TAX

8.1.
The Sellers shall not be liable in respect of [***] to the extent that:

(a)
it has been discharged or made good without cost or loss to the Buyer; or

(b)
it arises or is increased as a result of any increase in the rates of Tax
announced after the date of this Agreement; or

(c)
it arises or is increased by virtue of the failure or omission by the Company or
the Buyer to make any claim, election, surrender or disclaimer or give any
notice or consent or do any other thing after Completion (otherwise than at the
written request of the Sellers), the making, giving or doing of which was taken
into account or assumed in computing any provision or reserve for Tax in the
Completion Accounts; or

(d)
any Relief (other than a Relief which has been reflected or shown as an asset in
the Completion Accounts, or has been taken into account in calculating any
provisions for Tax in the Completion Accounts) is available to reduce or
eliminate such Tax liability.

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
78
 

--------------------------------------------------------------------------------

9.
CHANGE IN LAW

The Sellers shall not be liable in respect of any Claim to the extent that it
arises, or its value is increased, as a result of a change in any law,
legislation, rule or regulation (including any new law, legislation, rule or
regulation) that comes into force or otherwise takes effect after the date of
this Agreement.
10.
VOLUNTARY ACTS

10.1.
The Sellers shall not be liable in respect of any Claim to the extent that the
matter or circumstance giving rise to such Claim arises, occurs or is otherwise
attributable to, or the Sellers’ liability pursuant to such Claim is increased
as a result of:

[***].
10.2.
The Sellers shall not be liable in respect of any Claim to the extent that
[***].

11.
SET OFF

11.1.
Subject to the procedures set forth in paragraph 11.2 below, the Buyer shall be
entitled to deduct from the Contingent Consideration payable to a Seller or
Sellers when it becomes due and payable in accordance with the provisions of
Schedule 5 (Contingent Consideration), an amount equal to any Claim which may
exist at the date upon which the Contingent Consideration falls due to be paid
by the Buyer; provided, however, that in respect of [***], the Buyer may only
deduct or withhold from the Contingent Consideration payable to the Sellers the
proportion of the Contingent Consideration (as notified by the Sellers’
Representative pursuant to clause 3.5 of the Agreement) that is due or becomes
due to [***].

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
79
 

--------------------------------------------------------------------------------

11.2.
If in connection with a payment of Contingent Consideration that has become due
and payable in accordance with the provisions of Schedule 5 (Contingent
Consideration), the Buyer in good faith believes that a Claim exists and the
Buyer intends to make a deduction to such Contingent Consideration as permitted
under paragraph 11.1 above, the Buyer shall, within three (3) Business Days
following such payment becoming due and payable, deliver to the Sellers’
Representative and each Warrantor a notice in writing (a “Set Off Notice”) of
such Claim, which Set Off Notice shall state in reasonable detail the nature of
the Claim, the grounds on which it is based (including which Warranty has or
Warranties have been breached) and a good faith estimate of the amount claimed
(the “Set Off Claim”). If the Sellers’ Representative wishes to dispute the Set
Off Claim on behalf of the Sellers or any Seller, it may, within twenty (20)
Business Days of receipt of the Set Off Notice, indicate the same by written
notice to the Buyer (the “Set Off Dispute Notice”) which also shall state in
reasonable the basis for the Sellers’ Representative’s dispute and the grounds
on which it is based, in which case, either the Buyer or the Sellers’
Representative may then elect to initiate an alternative dispute resolution
proceeding pursuant to the procedures set forth in clause 23.3 for purposes of
having the Set Off Claim settled (a “Set Off ADR”)

11.3.
Promptly following timely receipt of the Set Off Dispute Notice, the Buyer shall
deposit the applicable Contingent Consideration into escrow with SunTrust Bank
or another escrow agent mutually acceptable to the Buyer and the Sellers’
Representative. The applicable Contingent Consideration shall be released from
escrow and paid in accordance with the decision of the arbitrators in such Set
Off ADR.

11.4.
For the avoidance of doubt, the set-off right set out in this paragraph 11 shall
not apply to [***].

12.
[***]

[***].
13.
CONDUCT OF THIRD PARTY CLAIMS

13.1.
The provisions of this paragraph 13 shall apply in the event that any third
party brings or makes (or threatens to bring or make) any claim, demand, action
or proceedings against any of the Buyer or a Buyer’s Group Undertaking which may
reasonably be considered likely to give rise to a Claim (a “Third Party Claim”).

13.2.
In the event of a Third Party Claim, the Buyer shall:

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
80
 

--------------------------------------------------------------------------------

(a)
as soon as reasonably practicable [***] give written notice of the Third Party
Claim to the Sellers’ Representative, specifying in reasonable detail the nature
of the Third Party Claim;

(b)
permit the Sellers’ Representative to participate in the defence of (but not
conduct or control) such Third Party Claim at the expense of the Sellers’
Representative;

(c)
keep the Sellers reasonably informed (through the Sellers’ Representative) of
the progress of, and all material developments in relation to, the Third Party
Claim;

(d)
provide the Sellers’ Representative with copies of all material information and
correspondence relating to the Third Party Claim; and

(e)
give (and cause each relevant Buyer’s Group Undertaking to give) the Sellers’
Representative and/or its professional advisers access at reasonable times (and
on reasonable prior notice) to its premises and personnel, and to any relevant
assets, accounts, documents or records within its control, for the purposes of
enabling the Sellers to assess the Third Party Claim and to exercise their
rights under this paragraph 13.2.

13.3.
The Buyer shall have the right in its sole discretion to conduct the defence of
and to settle or resolve such Third-Party Claim. However, without the prior
written consent of the Sellers’ Representative, which consent will not be
unreasonably withheld, delayed or conditioned [***]. In the event that the
Sellers’ Representative has consented in writing [***], neither the Sellers’
Representative nor any Seller shall have any power or authority to object [***].

13.4.
The Sellers shall indemnify the Buyer in respect of all costs, charges and
expenses that are reasonably and properly incurred by the Buyer (or any other
member of the Buyer’s Group) in connection with the defence of a Third Party
Claim.

14.
PROVISION OF INFORMATION

If, at any time after the date of this Agreement, a Seller wants to insure
against its liabilities in respect of a Claim, the Buyer shall provide such
information and assistance as a prospective insurer may reasonably require
before effecting the insurance.
15.
PRESERVATION OF INFORMATION

The Buyer shall, and shall ensure that each Buyer Group Company will, use
reasonable endeavours to preserve all documents, records, correspondence,
accounts and other information whatsoever relevant to a matter which may give
rise to a Claim.
*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

CONFIDENTIAL
81
 

--------------------------------------------------------------------------------

16.
RELEASING SELLER FROM LIABILITY

The Buyer may release or compromise in whole or in part the liability of any of
the Sellers under this Agreement or grant any time or indulgence to that Seller
without affecting the liability of any other Seller.
17.
CONTINGENT LIABILITIES

If any potential Claim arises as a result of a contingent or unquantifiable
liability of any Buyer’s Group Undertaking, each Seller will not be obliged to
pay any sum in respect of the potential Claim until the liability either ceases
to be contingent or becomes quantifiable; provided, however, that this paragraph
17 shall not restrict the Buyer from setting off and deducting the Buyer’s
reasonable estimate of any such potential Claim from Contingent Consideration,
as permitted by paragraph 11.

CONFIDENTIAL
82
 

--------------------------------------------------------------------------------

EXECUTED and DELIVERED as a DEED by DENALI THERAPEUTICS INC. acting by an
authorised officer
)
)
)

…/s/ Steve Krognes…………………………
In the presence of:
 
 
 
 
 
Signature of Witness:
 
…………………………………………….
 
 
 
Name of Witness:
 
…………………………………………….
 
 
 
Address of Witness:
 
…………………………………………….

 
 
…………………………………………….
 
 
 
Occupation of Witness:
 
…………………………………………….
 
 
 

CONFIDENTIAL
83
 

--------------------------------------------------------------------------------

EXECUTED and DELIVERED as a DEED by SHAREHOLDER REPRESENTATIVE SERVICES
LLC. acting by an authorised officer
)
)
)

…/s/ [***]…………………………………
In the presence of:
 
 
Signature of Witness:
 

…………………………………………….
 
 
 
Name of Witness:
 
…………………………………………….
 
 
 
Address of Witness:
 
…………………………………………….

 
 
…………………………………………….
 
 
 
Occupation of Witness:
 
…………………………………………….
 
 
 

CONFIDENTIAL
84
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

EXECUTED and DELIVERED as a DEED by [***]
an authorised signatory of
ATLAS VENTURE ASSOCIATES VII, INC. acting in its capacity as general partner of
ATLAS VENTURE ASSOCIATES VII, L.P. acting in its capacity as general partner
of ATLAS VENTURE FUND VII, L.P.

In the presence of:

…/s/ [***]……………………………………

Signature of Witness:

………………………………………………….

Name of Witness:

………………………………………………….

Address of Witness: 

………………………………………………….

………………………………………………….

…………………………………………………

Occupation of Witness:

………………………………………………….

CONFIDENTIAL
85
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

EXECUTED and DELIVERED as a DEED
by [***]
an authorised signatory of
AESCAP VENTURE MANAGEMENT B.V. acting as manager of
COÖPERATIVE AESCAP VENTURE I U.A.

In the presence of:

…/s/ [***]……………………………………

Signature of Witness: 

………………………………………………….
Name of Witness:
………………………………………………….
Address of Witness:
………………………………………………….
………………………………………………….
…………………………………………………
Occupation of Witness:
………………………………………………….

CONFIDENTIAL
86
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

EXECUTED and DELIVERED as a DEED by TVM LIFE SCIENCE VENTURES VI GMBH & CO.
KG acting by ________________________, authorised signatory

In the Presence of:

…/s/ [***]……………………………………

Signature of Witness:

………………………………………………….
Name of Witness:
………………………………………………….
Address of Witness:
………………………………………………….
………………………………………………….
…………………………………………………
Occupation of Witness:
………………………………………………….

CONFIDENTIAL
87
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

EXECUTED and DELIVERED as a DEED by ______________________, authorised signatory
of TVM LIFE SCIENCE VENTURES VI CAYMAN LIMITED acting as a general partner of
TVM LIFE SCIENCE VENTURES VI LIMITED PARTNERSHIP

In the Presence of:

…/s/ [***]……………………………………

Signature of Witness:

………………………………………………….
Name of Witness:
………………………………………………….
Address of Witness:
………………………………………………….
………………………………………………….
…………………………………………………
Occupation of Witness:
………………………………………………….

CONFIDENTIAL
88
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

EXECUTED and DELIVERED as a DEED by MP HEALTHCARE VENTURE MANAGEMENT, INC.
acting by _______________________, an authorised signatory
In the Presence of:

…/s/ [***]…………………………………

Signature of Witness:

…………………………………………….
Name of Witness:
…………………………………………….
Address of Witness:
…………………………………………….
…………………………………………….
…………………………………………….
Occupation of Witness:
…………………………………………….

CONFIDENTIAL
89
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

EXECUTED and DELIVERED as a DEED by MERCK VENTURES B.V. acting by
_______________________, an authorised signatory
In the Presence of:

…/s/ [***]……………………………………

Signature of Witness:

………………………………………………….
Name of Witness:
………………………………………………….
Address of Witness: 
………………………………………………….
………………………………………………….
…………………………………………………
Occupation of Witness:
………………………………………………….

CONFIDENTIAL
90
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

EXECUTED and DELIVERED as a DEED by S.R. ONE, LIMITED acting by [***], a
duly authorised officer 
In the Presence of:

…/s/ [***]……………………………………

Signature of Witness:

………………………………………………….
Name of Witness:
………………………………………………….
Address of Witness:
………………………………………………….
………………………………………………….
…………………………………………………
Occupation of Witness:
………………………………………………….

CONFIDENTIAL
91
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.

--------------------------------------------------------------------------------

EXECUTED and DELIVERED as a DEED by [***]
In the Presence of:

…/s/ [***]……………………………………

Signature of Witness:

………………………………………………….
Name of Witness:
………………………………………………….
Address of Witness:
………………………………………………….
………………………………………………….
………………………………………………….
Occupation of Witness:
………………………………………………….

CONFIDENTIAL
92
 

*** Certain information in this agreement has been omitted and filed separately
with the Securities and Exchange Commission. [***] indicates that text has been
omitted and is the subject of a confidential treatment request.